

RESUME

Prof. Mohammad Amjad Kamal (PhD; FRACI C Chem)



Enzymoics; Novel Global Community Educational Foundation
7 Peterlee Place, Hebersham, NSW 2770, Australia

- Justice of peace, Dept. of Justice & Attorney G., Australia

SPECIALITY:

Biochemistry, Neuroscience, Enzymology, Toxicology, Metabolomics, Nanomedicines, Manual lymph Drainage & miRNA, Leadership in Managing Staff Performance and Chaplaincy

RESPONSIBILITY:

To lead my global research team (more than 100 scientists around the world) in the field of neuroscience research (neurodegenerative disorders such as Alzheimer & Parkinson) type 2 diabetes mellitus and cancer

NUMBER OF PUBLICATIONS: Over 550 **NUMBER OF ABSTRACTS:** 65

<http://www.ncbi.nlm.nih.gov/pubmed/?term=kamal-ma>

<http://www.researcherid.com/rid/J-2918-2014>

NATIONALITY: Australian

EMPLOYMENT HISTORY

From 16 th Jan 2013	Distinguished Adjunct Professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia
From 4 th March 2019	Cultural Support Worker (Education Officer), NSW Health, SLHD
From 12 th Feb 2016	Founding President and Director , Novel Global Community Educational Foundation
23 Jan 2019- 17 April 2019	Educational Administrator , Giant Steps Tasmania
Jan 2012 to Jan 2014	Coordinator of KFMRC Publication Committee (KPC)
March 2011 to Nov 2013	Research Group Leader (RGL) of "Fundamental and Applied Biology Group"
March 2011 to March 2013	Professor at King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
Feb 2012 until now	Research Unit Coordinator of Metabolomics & Enzymology Unit

RESUME

Prof. Mohammad Amjad Kamal (PhD; FRACI C Chem)

- From Jan 2004-until now **Lead Scientist**, Enzymoics/Enzymoic
- Jan 2010 to Jan 2012 **Adjunct** (equal to Full Professor) in Dr Nigel H. Greig's scientific research group "Drug Design & Development Section", National Institute on Aging (NIA), National Institutes of Health (NIH), USA
- 
- July 2007 to Dec 2009 **Visiting Scholar**, Department of Medical & Molecular BioSciences, University of Technology, Sydney, Australia
- 
- March 2008 to May 2008 **Contractor**, Review Section, Office of Chemical Safety, Department of Health and Aging, Canberra
- Oct 2003 to March 2004 **Honorary Associate** at School of Molecular and Microbial Biosciences, University of Sydney, Australia
- July 2000 - July 2003 **U2000 Postdoctoral Fellowship** awarded by University of Sydney, School of Molecular and Microbial Biosciences, G08, Sydney, Australia (Focus on the inhibition of the rate-limiting enzyme, amido phosphoribosyltransferase, that catalyzes the first committed step of the *de novo* purine pathway)
- 
- Dec 1990 to June 2000 **Research Assistant**, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
- Jan 1987 to Dec 1990 **Lecturer** at Department of Chemistry, Gomal University, D. I. Khan, Pakistan

EDUCATION:

1986 Master of Science (specialization in Biochemistry), Chemistry Department, Gomal University, Pakistan

1999 Doctoral of Philosophy, Chemistry Department, Islamia University, Bahawalpur, Pakistan

RESEARCH:

To discover new drugs particularly for the treatment of Alzheimer's, diabetes and cancer diseases. Type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD) affect a large percentage of the population throughout industrialized countries. Both diseases occur more often with advancing age. Epidemiological studies have shown an association between T2DM and AD, which are frequently detected together. Experimental studies have revealed that T2DM and AD share several molecular processes that underlie the respective degenerative pathology in the brain and in pancreatic β -cells. Therefore, based on the scientific literature, we target our research on the inhibition of butyrylcholinesterase and cytokine markers such as TNF- α and IL 6.

HONOURS AND AWARDS:

- 21st Century Award for Achievement in recognition of outstanding contribution (offered by the Director-General on the approval of editorial review board of International Biographical Centre, Cambridge, England, 5th May 2006)
- Travel Fellowship Award for the presentation of “Interaction of New anti-Alzheimer's Disease Agents with Cholinesterase” in ISN – ESN- 20th Biennial meeting in Innsbruck Austria, August 2005.
- Sheikh Hamdan Bin Rashid Al Maktoum Award in 2004 for Medical Sciences for an original research paper published in the Emirates Medical Journal in Dec. 2002
- Young Researchers Award Awarded by the first Forum for European-Australian Science and Technology Cooperation event (FEAST 1) in May 2001 in Canberra
- U2000 Postdoctoral Fellowship Awarded in 2000 by the University of Sydney, Australia
- Travel Fellowship Award From the Int. Society for Neurochemistry, granted for participation in the Xth Int. Sym. on Cholinergic Mechanisms, Arcachon, France, Sep. 1998.

MAJOR ACHIEVEMENTS:

Significant contribution in discovery of new potential agents for the treatment of Alzheimer's and related neurodegenerative diseases via collaboration with Dr Nigel H. Greig, Chief, Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Biomedical Research Center, Baltimore, MD, USA

Development of new techniques to define and quantify enzyme-substrate interactions; In addition, a thin layer chromatographic assay was developed for the measurement of phosphoribosylpyrophosphate extracted from human CCRF-CEM leukaemia cells growing in cell culture for the development of new anti-cancer drugs.

Research related to the interaction of various chemicals and drugs (both anti-cancer and Alzheimer's agents) with the key enzyme acetylcholinesterase (which is fundamental to the function of the nervous system). The research was pivotal in supporting the development of the novel drug Phenserine, from the laboratory to the clinic. Specifically, the essential elucidation of the kinetics of Phenserine aided in the application and approval of an Investigational New Drug Application by the United States Government Food and Drug Administration to allow the use of the compound in humans to assess its utility in the treatment of Alzheimer's disease.

LIST OF PUBLICATIONS:**2020:**

- 1: Nadeem MS, Kumar V, Al-Abbasi FA, Kamal MA, Anwar F. Risk of colorectal cancer in inflammatory bowel diseases. *Semin Cancer Biol.* 2020 Aug;64:51-60. doi: 10.1016/j.semcancer.2019.05.001. Epub 2019 May 18. PMID: 31112753.

- 2: Farran B, Montenegro RC, Kasa P, Pavitra E, Huh YS, Han YK, Kamal MA, Nagaraju GP, Rama Raju GS. Folate-conjugated nanovehicles: Strategies for cancer therapy. *Mater Sci Eng C Mater Biol Appl*. 2020 Feb;107:110341. doi: 10.1016/j.msec.2019.110341. Epub 2019 Oct 23. PMID: 31761235.
- 3: Anwar F, Altayb HN, Al-Abbasi FA, Al-Malki AL, Kamal MA, Kumar V. Antiviral effects of probiotic metabolites on COVID-19. *J Biomol Struct Dyn*. 2020 Jun 9:1-10. doi: 10.1080/07391102.2020.1775123. Epub ahead of print. PMID: 32475223; PMCID: PMC7298884.
- 4: Tabrez S, Jabir NR, Khan MI, Khan MS, Shakil S, Siddiqui AN, Zaidi SK, Ahmed BA, Kamal MA. Association of autoimmunity and cancer: An emphasis on proteolytic enzymes. *Semin Cancer Biol*. 2020 Aug;64:19-28. doi: 10.1016/j.semcancer.2019.05.006. Epub 2019 May 14. PMID: 31100322.
- 5: Nagaraju GP, Srivani G, Dariya B, Chalikonda G, Farran B, Behera SK, Alam A, Kamal MA. Nanoparticles guided drug delivery and imaging in gastric cancer. *Semin Cancer Biol*. 2020 Jan 16:S1044-579X(20)30007-9. doi: 10.1016/j.semcancer.2020.01.006. Epub ahead of print. PMID: 31954835.
- 6: Islam MA, Kamal MA, Gan SH, Alam F. Autoimmune disease and cancer comorbidity: Current understandings of immune-mediated pathogenesis and treatment. *Semin Cancer Biol*. 2020 Aug;64:iii-iv. doi: 10.1016/j.semcancer.2019.10.001. Epub 2019 Oct 4. PMID: 31589922.

7: Nadeem MS, Al-Abbasi FA, Kazmi I, Murtaza BN, Zamzami MA, Kamal MA, Arif A, Afzal M, Anwar F. Multiple Risk Factors: A Challenge in the Management of Autism. *Curr Pharm Des.* 2020;26(7):743-754. doi:

10.2174/1381612826666200226101218. PMID: 32101114.

8: Sharma N, Sharma M, Sajid Jamal QM, Kamal MA, Akhtar S. Nanoinformatics and biomolecular nanomodeling: a novel move en route for effective cancer treatment.

Environ Sci Pollut Res Int. 2020 Jun;27(16):19127-19141. doi:

10.1007/s11356-019-05152-8. Epub 2019 Apr 25. PMID: 31025282.

9: Kamal MA, Al-Zahrani MH, Khan SH, Khan MH, Al-Subhi HA, Kuerban A, Aslam M, Al-Abbasi FA, Anwar F. Tubulin Proteins in Cancer Resistance: A Review. *Curr*

Drug Metab. 2020;21(3):178-185. doi: 10.2174/1389200221666200226123638. PMID: 32101117.

10: Bakir S, Catalkaya G, Ceylan FD, Khan H, Guldiken B, Capanoglu E, Kamal MA.

Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing? *Curr Pharm Des.* 2020;26(7):714-729. doi:

10.2174/1381612826666200107143619. PMID: 31914905.

11: Jamal QMS, Siddiqui MU, Alharbi AH, Albejaidi F, Akhtar S, Alzohairy MA, Kamal MA, Kesari KK. A Computational Study of Natural Compounds from *Bacopa monnieri* in the Treatment of Alzheimer's Disease. *Curr Pharm Des.*

2020;26(7):790-800. doi: 10.2174/1381612826666200102142257. PMID: 31894743.

12: Yousafi Q, Azhar M, Khan MS, Mehmood A, Saleem S, Sajid MW, Hussain A, Kamal MA. Interaction of human dynein light chain 1 (DYNLL1) with enterochelin esterase (*Salmonella typhimurium*) and protective antigen (*Bacillus anthracis*) might be the potential cause of human infection. Saudi J Biol Sci. 2020 May;27(5):1396-1402. doi: 10.1016/j.sjbs.2019.11.034. Epub 2019 Dec 2. PMID: 32346352; PMCID: PMC7182775.

13: Arshad AI, Ahmad P, Karobari MI, Asif JA, Alam MK, Mahmood Z, Abd Rahman N, Mamat N, Kamal MA. Antibiotics: A Bibliometric Analysis of Top 100 Classics. Antibiotics (Basel). 2020 Apr 29;9(5):219. doi: 10.3390/antibiotics9050219. PMID: 32365471; PMCID: PMC7277750.

14: Tyagi A, Kamal MA, Poddar NK. Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer's Disease. Front Neurosci. 2020 Jul 9;14:693. doi: 10.3389/fnins.2020.00693. PMID: 32742252; PMCID: PMC7364283.

15: Kamal MA, Abdel-Daim MM. Current Challenges in Management of Neurological Disorders (Part-I). Curr Pharm Des. 2020;26(7):711-713. doi: 10.2174/138161282607200309122739. PMID: 32223726.

16: Arslan J, Gilani AU, Jamshed H, Khan SF, Kamal MA. Edible Nuts for Memory. Curr Pharm Des. 2020 Aug 5. doi: 10.2174/1381612826666200806095649. Epub ahead of print. PMID: 32767923.

17: Birru B, Durthi CP, Kacham S, Pola M, Rajulapati SB, Parcha SR, Kamal MA.

Stem Cells in Tumour Microenvironment Aid in Prolonged Survival Rate of Cancer

Cells and Developed Drug Resistance: Major Challenge in Osteosarcoma Treatment.

Curr Drug Metab. 2020;21(1):44-52. doi: 10.2174/1389200221666200214120226. PMID: 32056519.

18: Nagaraju GP, Kamal MA. Challenges in the Discovery of Novel Therapeutic

Agents for Cancer Treatment (Part IV). Curr Drug Metab. 2020;21(3):165-166. doi:

10.2174/138920022103200604143047. PMID: 32608350.

19: Kamal MA, Nagaraju GP. Challenges in the Discovery of Novel Therapeutic

Agents in Cancer (Part III). Curr Drug Metab. 2020;21(1):4-5. doi:

10.2174/138920022101200429122759. PMID: 32423370.

20: Anwar F, Naqvi S, Al-Abbasi FA, Neelofar N, Kumar V, Sahoo A, Kamal MA.

Targeting COVID-19 in Parkinson's patients: Drugs repurposed. Curr Med Chem.

2020 Sep 3. doi: 10.2174/0929867327666200903115138. Epub ahead of print. PMID: 32881656.

21: Khan S, Ahmad SS, Kamal MA. Diabetic Cardiomyopathy: From Mechanism to

Management in a Nutshell. Endocr Metab Immune Disord Drug Targets. 2020 Jul 31.

doi: 10.2174/1871530320666200731174724. Epub ahead of print. PMID: 32735531.

22: Raj S, Chandel V, Kumar A, Kesari KK, Asthana S, Ruokolainen J, Kamal MA,

Kumar D. Molecular mechanisms of interplay between autophagy and metabolism in

cancer. Life Sci. 2020 Aug 5;259:118184. doi: 10.1016/j.lfs.2020.118184. Epub

ahead of print. PMID: 32763290.

23: Tabrez S, Jabir NR, Adhami VM, Khan MI, Moulay M, Kamal MA, Mukhtar H.

Nanoencapsulated dietary polyphenols for cancer prevention and treatment:

successes and challenges. *Nanomedicine (Lond)*. 2020 May;15(11):1147-1162. doi:

10.2217/nmm-2019-0398. Epub 2020 Apr 15. PMID: 32292109.

24: Rahman MH, Akter R, Behl T, Chowdhury MAR, Manirujjaman M, Bulbul IJ,

Elshenawy SE, Kamal MA. COVID-19 Outbreak and Emerging Management through

Pharmaceutical Therapeutic Strategy. *Curr Pharm Des*. 2020 Jul 13. doi:

10.2174/1381612826666200713174140. Epub ahead of print. PMID: 32660401.

25: Mueed Z, Mehta D, Rai PK, Kamal MA, Poddar NK. Cross-Interplay between

Osmolytes and mTOR in Alzheimer's disease pathogenesis. *Curr Pharm Des*. 2020 May

18. doi: 10.2174/1381612826666200518112355. Epub ahead of print. PMID: 32418522.

26: Rahman MH, Akter R, Kamal MA. Prospective Function of Different Antioxidant

Containing Natural Products in the Treatment of Neurodegenerative Disease. *CNS*

Neurol Disord Drug Targets. 2020 Jul 22. doi: 10.2174/1871527319666200722153611.

Epub ahead of print. PMID: 32703143.

27: Mueed Z, Rai PK, Kamal MA, Poddar NK. Decoding the Inter-relationship

between Sleep Disorders and Alzheimer's disease Pathogenesis. *CNS Neurol Disord*

Drug Targets. 2020 Sep 3. doi: 10.2174/1871527319666200903161249. Epub ahead of

print. PMID: 32885762.

28: Liu S, Dang M, Lei Y, Ahmad SS, Khalid M, Kamal MA, Chen L. Ajmalicine and its Analogues against AChE and BuChE for the Management of Alzheimer's Disease: An In-silico study. *Curr Pharm Des.* 2020 Apr 7. doi: 10.2174/1381612826666200407161842. Epub ahead of print. PMID: 32264807.

29: Phull AR, Ali A, Ali A, Abbasi S, Zia M, Khaskheli MH, Haq IU, Kamal MA. Synthesis of Silver Nanoparticles using *Euphorbia wallichii* Extract and Assessment of their Bio-functionalities. *Med Chem.* 2020;16(4):495-506. doi: 10.2174/1573406415666191111143213. PMID: 31713490.

30: Chandel V, Raj S, Kumar P, Gupta S, Dhasmana A, Kesari KK, Ruokolainen J, Mehra P, Das BC, Kamal MA, Kumar D. Metabolic regulation in HPV associated head and neck squamous cell carcinoma. *Life Sci.* 2020 Aug 11;258:118236. doi: 10.1016/j.lfs.2020.118236. Epub ahead of print. PMID: 32795537.

31: Hassan W, Kamdem JP, Kamal MA, da Rocha JBT. Bibliometric Analysis of Current Drug Metabolism: The Twenty Years Anniversary From 2000-2019. *Curr Drug Metab.* 2020 Aug 25. doi: 10.2174/1389200221666200826094233. Epub ahead of print. PMID: 32851957.

32: Malik RM, Fazal S, Kamal MA. Computational analysis of domains vulnerable To HPV-16 E6 Oncoprotein and corresponding hot spot residues. *Protein Pept Lett.* 2020 Jul 22. doi: 10.2174/0929866527666200722134801. Epub ahead of print. PMID: 32703126.

33: Durthi CP, Pola M, Rajulapati SB, Kola AK, Kamal MA. Versatile and Valuable Utilization of Amidohydrolase L-glutaminase in Pharma and Food industries: A Review. *Curr Drug Metab.* 2020;21(1):11-24. doi: 10.2174/1574884715666200116110542. PMID: 31951174.

34: Alshammary F, Siddiqui AA, Amin J, Ilyas M, Rathore HA, Hassan I, Alam MK, Kamal MA. Prevention Knowledge and Its Practice Towards COVID-19 Among General Population of Saudi Arabia: A Gender-based Perspective. *Curr Pharm Des.* 2020 Aug 18. doi: 10.2174/1381612826666200818213558. Epub ahead of print. PMID: 32811408.

35: Bibi N, Gul S, Ali J, Kamal MA. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. *Eur J Pharmacol.* 2020 Aug 22:173496. doi: 10.1016/j.ejphar.2020.173496. Epub ahead of print. PMID: 32841640; PMCID: PMC7443089.

36: Saeed M, Kushvaha V, Faisal SM, Verma R, Ahmad I, Mustafa H, Ganash M, Kamal MA, Ashraf GM. A Study On Serological Reactivity Profile Of Different Antigen Preparations With Bancroftian Filariasis Human Infection Sera. *Protein Pept Lett.* 2020 Feb 25. doi: 10.2174/0929866527666200225123534. Epub ahead of print. PMID: 32096736.

37: Asif M, Usman M, Ayub S, Farhat S, Huma Z, Ahmad J, Kamal MA, Hussein D, Javed A, Khan I. Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates. *Curr Pharm Des.* 2020

Feb 23. doi: 10.2174/1381612826666200224112141. Epub ahead of print. PMID: 32091329.

38: Sghaireen MG, Srivastava KC, Shrivastava D, Ganji KK, Patil SR, Abuonq A, Mousa MA, Dar-Odeh N, Sghaireen GM, Kamal MA, Alam MK. A CBCT Based Three-Dimensional Assessment of Mandibular Posterior Region for Evaluating the Possibility of Bypassing the Inferior Alveolar Nerve While Placing Dental Implants. *Diagnostics (Basel)*. 2020 Jun 14;10(6):406. doi: 10.3390/diagnostics10060406. PMID: 32545908; PMCID: PMC7344927.

39: Bibi N, Hupp T, Kamal MA, Rashid S. Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1- Linked Functions Crosstalk. *Protein Pept Lett*. 2020 Sep 1. doi: 10.2174/0929866527999200901201837. Epub ahead of print. PMID: 32875973.

2019:

1. Risk of colorectal cancer in inflammatory bowel diseases. Nadeem MS, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31112753
2. Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. Mueed Z, et al. *Front Neurosci* 2019 - *Review*. Among authors: **Kamal MA**. PMID 30686983
3. Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus Alam F, et al. *Endocr Metab Immune Disord Drug Targets* 2019. Among authors: **Kamal MA**. PMID 31530259
4. Editorial: The Alzheimer's Disease Challenge. Alexiou A, et al. *Front Neurosci* 2019. Among authors: **Kamal MA**. PMID 31396043
5. Horizons of nanotechnology applications in female specific cancers Rajitha B, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31301361

6. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Pottou FH, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31562954
7. Engineered nanoparticles for imaging and drug delivery in colorectal cancer Pavitra E, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31260733
8. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. Samie HAA, et al. *Curr Drug Metab* 2019 - *Review*. Among authors: **Kamal MA**. PMID 30854953
9. Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects Khan H, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31374244
10. What is Blockchain Technology and its Significance in the Current Healthcare System? A Brief Insight. Ahmad SS, et al. *Curr Pharm Des* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31258067
11. Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy Aiello P, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31454670
12. Editorial: Neuroscientific Research for Management of Dementia **Kamal MA** and Nasrallah FA. *Front Aging Neurosci* 2019. PMID 30930763 Free PMC article.
13. Role of GTPases in the Regulation of Mitochondrial Dynamics in Alzheimer's Disease and CNS-Related Disorders Alexiou A, et al. *Mol Neurobiol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 30338485
14. Challenges in the Discovery of Novel Therapeutic Agents in Cancer Nagaraju GP and **Kamal MA**. *Curr Drug Metab* 2019. PMID 32072882
15. Current Updates on the Regulation of Beta-Secretase Movement as a Potential Restorative Focus for Management of Alzheimer's Disease Ahmad SS and **Kamal MA**. *Protein Pept Lett* 2019 - *Review*. PMID 30950339
16. Immune-mediated Pathogenesis and Therapies for Inflammatory Autoimmune Diseases. Islam MA, et al. *Curr Pharm Des* 2019. Among authors: **Kamal MA**. PMID 31621552
17. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Raj S, et al. *Semin Cancer Biol* 2019 - *Review*. Among authors: **Kamal MA**. PMID 31715247
18. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Alam F, et al. *Sci Rep* 2019. Among authors: **Kamal MA**. PMID 30926892 Free PMC article.

19. Nonpharmacologic Interventions in Prevention and Treatment of Hypertension
Erejuwa OO, et al. *Int J Hypertens* 2019. Among authors: **Kamal MA**. PMID 31001431 Free PMC article.
20. Special issue: Current vision on target enzymes for cancer therapy
Bishayee A and Kamal MA. *Semin Cancer Biol* 2019. PMID 30503852
21. Association of autoimmunity and cancer: An emphasis on proteolytic enzymes
Tabrez S, et al. *Semin Cancer Biol* 2019 - *Review*. PMID 31100322
22. Concept of Drug Metabolism in Drug Discovery Pipeline
Ahmad SS and Kamal MA. *Curr Drug Metab* 2019. PMID 31722656
23. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
Lakkakula BVKS, et al. *Semin Cancer Biol* 2019 - *Review*. PMID 30314681
24. A Paradigm Shift in the Development of Anti-Candida Drugs
Gowda DV, et al. *Curr Top Med Chem* 2019 - *Review*. PMID 31663480
25. The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer. Qu J, et al. *Curr Pharm Des* 2019 - *Review*. PMID 30947657
26. Challenges in the Discovery of Novel Therapeutic Agents in Cancer
Nagaraju GP and Kamal MA. *Curr Drug Metab* 2019. PMID 31989914
27. Autoimmune disease and cancer comorbidity: Current understandings of immune-mediated pathogenesis and treatment. Islam MA, et al. *Semin Cancer Biol* 2019. PMID 31589922
28. An increasing role of polyphenols as novel therapeutics for Alzheimer's: A review
Karim N, et al. *Med Chem* 2019. PMID 31702507
29. Nanomedicine in treatment of breast cancer - A challenge to conventional therapy. Afzal M, et al. *Semin Cancer Biol* 2019 - *Review*. PMID 31870940
30. Chemokines: A Potential Therapeutic Target to Suppress Autoimmune Arthritis
Khan MA, et al. *Curr Pharm Des* 2019. PMID 31580792
31. Zika Virus Targeting by Screening Inhibitors against NS2B/NS3 Protease
Choudhry H, et al. *Biomed Res Int* 2019. PMID 31886207 Free PMC article.
32. Enzyme targeting strategies for prevention and treatment of cancer: Implications for cancer therapy. Baig MH, et al. *Semin Cancer Biol* 2019 - *Review*. PMID 29248538
33. Non-coding RNAs in Lung Cancer Chemoresistance. Mondal P, et al. *Curr Drug Metab* 2019. PMID 31906835
34. Can Wogonin be Used in Controlling Diabetic Cardiomyopathy? Khan S and Kamal MA. *Curr Pharm Des* 2019. PMID 31298148

35. The Structure and Function of α , β and γ -Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review
Ahmad SS, et al. CNS Neurol Disord Drug Targets 2019. PMID 31608840
36. Folate-conjugated nanovehicles: Strategies for cancer therapy.
Farran B, Montenegro RC, Kasa P, Pavitra E, Huh YS, Han YK, Kamal MA, Nagaraju GP, Rama Raju GS. Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110341. doi: 10.1016/j.msec.2019.110341. Epub 2019 Oct 23
37. Screening and Identification of PLK1-Polo Box Binding Peptides by High-Throughput Sequencing of Phage-Selected Libraries
Bibi N, et al. Protein Pept Lett 2019. PMID 30887917
38. Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
Bibi N, et al. Curr Pharm Des 2019. PMID 31368868
39. Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway. Khan S and Kamal MA. Curr Pharm Des 2019. PMID 31333118
40. Therapeutic Study of Phytochemicals Against Cancer and Alzheimer's Disease Management. Ahmad SS, et al. Curr Drug Metab 2019. PMID 31902351
41. Protective effects of raspberry on the oxidative damage in HepG2 cells through Keap1/Nrf2-dependent signaling pathway. Chen L, et al. Food Chem Toxicol 2019. PMID 31465820
42. Erratum to "Nonpharmacologic Interventions in Prevention and Treatment of Hypertension". Erejuwa OO, et al. Int J Hypertens 2019. PMID 31737360 Free PMC article. [This corrects the article DOI: 10.1155/2019/6709817.]....
43. NMR: From molecular mechanism to its application in medical care. Zhang Z, et al. Med Chem 2019. PMID 31713489
44. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Cork MJ, et al. Br J Dermatol 2020. PMID 31595499 Free PMC article.
45. Nanoinformatics and biomolecular nanomodeling: a novel move en route for effective cancer treatment
Sharma N, et al. Environ Sci Pollut Res Int 2019. PMID 31025282
46. Relationship between road traffic features and accidents: An application of two-stage decision-making approach for transportation engineers
Shah SAR, et al. J Safety Res 2019. PMID 31235230
47. Computational Protein-Protein Docking Reveals the Therapeutic Potential of Kunitz-type Venom against hKv1.2 Binding Sites. Khalid R, et al. CNS Neurol Disord Drug Targets 2019. PMID 30892167

48. Structural insights into the camel milk lactoperoxidase: Homology modeling and molecular dynamics simulation studies. Sheikh IA, et al. *J Mol Graph Model* 2019. PMID 30326373
49. Prospects for discovering the secondary metabolites of *Cordyceps sensu lato* by the integrated strategy. Bibi S, et al. *Med Chem* 2019. PMID 31880251
50. Synthesis of silver nanoparticles using *Euphorbia wallichii* extract and assessment of their bio-functionalities. Phull AR, et al. *Med Chem* 2019. PMID 31713490
51. In Silico Structure Modeling and Molecular Docking Analysis of Phosphoribosyl Pyrophosphate Amidotransferase (PPAT) with Antifolate Inhibitors. Bibi N, et al. *Curr Cancer Drug Targets* 2019. PMID 30479216
52. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions. Sharma AK, et al. *Curr Drug Metab* 2019. PMID 30207227
53. Molecular Docking studies reveals Rhein from rhubarb (*Rheum rhabarbarum*) as a putative inhibitor of ATP-binding Cassette Super Family G member 2. Khan MS, et al. *Med Chem* 2019. PMID 31854281

2018:

- 1: Yang L, Wei W, He X, Xie Y, Kamal MA, Li J. Influence of Hormones on Sjögren's Syndrome. *Curr Pharm Des.* 2018;24(35):4167-4176. doi: 10.2174/1381612824666181010153536. PubMed PMID: 30724137.
- 2: Peluso I, Abdel-Daim M, Yarla NS, Kamal MA. Complementary and Integrative Medicine: Personalized Health Care for Cancer and Chronic Inflammatory Diseases. *Curr Pharm Des.* 2018;24(35):4091-4092. doi: 10.2174/138161282435190117102756. PubMed PMID: 30724136.
- 3: Gupta GK, Kamal MA. Updates on Neurodegenerative and Metabolic Disorders: Synthetic, Biological and Computational Aspects. *Curr Med Chem.* 2018;25(39):5291-5292. doi: 10.2174/092986732539181119142202. PubMed PMID: 30688177.
- 4: Mueed Z, Tandon P, Maurya SK, Deval R, Kamal MA, Poddar NK. Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. *Front Neurosci.* 2019 Jan 10;12:1017. doi: 10.3389/fnins.2018.01017. eCollection 2018. Review. PubMed PMID: 30686983; PubMed Central PMCID: PMC6335350.
- 5: Singla RK, Ali M, Kamal MA, Dubey AK. Isolation and Characterization of

Nuciferoic Acid, a Novel Keto Fatty Acid with Hyaluronidase Inhibitory Activity from *Cocos nucifera* Linn. *Endocarp. Curr Top Med Chem.* 2018;18(27):2367-2378. doi: 10.2174/1568026619666181224111319. PubMed PMID: 30582479.

6: Sayeed U, Wadhwa G, Sajid Jamal QM, Kamal MA, Akhtar S, Siddiqui MH, Khan MS. MHC binding peptides for designing of vaccines against Japanese encephalitis virus: A computational approach. *Saudi J Biol Sci.* 2018 Dec;25(8):1546-1551. doi: 10.1016/j.sjbs.2016.01.041. Epub 2016 Feb 3. PubMed PMID: 30581316; PubMed Central PMCID: PMC6302886.

7: Sohrab SS, Suhail M, Ali A, Kamal MA, Husen A, Ahmad F, Azhar EI, Greig NH. Role of viruses, prions and miRNA in neurodegenerative disorders and dementia. *Virusdisease.* 2018 Dec;29(4):419-433. doi: 10.1007/s13337-018-0492-y. Epub 2018 Sep 29. Review. PubMed PMID: 30539044; PubMed Central PMCID: PMC6261888.

8: Bishayee A, Kamal MA. Special issue: Current vision on target enzymes for cancer therapy. *Semin Cancer Biol.* 2018 Nov 29. pii: S1044-579X(18)30174-3. doi: 10.1016/j.semcancer.2018.11.010. [Epub ahead of print] PubMed PMID: 30503852.

9: Bibi N, Parveen Z, Nawaz MS, Kamal MA. Insilico structure modeling and molecular docking analysis of phosphoribosyl pyrophosphate amidotransferase (PPAT) with antifolate inhibitors. *Curr Cancer Drug Targets.* 2018 Nov 26. doi: 10.2174/1568009619666181127115015. [Epub ahead of print] PubMed PMID: 30479216.

10: Peluso I, Palmery M, Yarla NS, Perry G, Kamal MA. From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy, and Neuropsychological Factors. *Oxid Med Cell Longev.* 2018 Sep 30;2018:6352689. doi: 10.1155/2018/6352689. eCollection 2018. PubMed PMID: 30363930; PubMed Central PMCID: PMC6186310.

11: Alexiou A, Soursou G, Chatzichronis S, Gasparatos E, Kamal MA, Yarla NS, Perveen A, Barreto GE, Ashraf GM. Role of GTPases in the Regulation of Mitochondrial Dynamics in Alzheimer's Disease and CNS-Related Disorders. *Mol Neurobiol.* 2019 Jun;56(6):4530-4538. doi: 10.1007/s12035-018-1397-x. Epub 2018 Oct 18. Review. PubMed PMID: 30338485.

12: Wei W, Ahmad SS, Chi S, Xie Y, Kamal MA, Li J. From Molecular Mechanism to the Etiology of Sjogren Syndrome. *Curr Pharm Des.* 2018;24(35):4177-4185. doi: 10.2174/1381612824666181016154033. PubMed PMID: 30332943.

13: Sheikh IA, Jiffri EH, Ashraf GM, Kamal MA. Structural insights into the camel

milk lactoperoxidase: Homology modeling and molecular dynamics simulation studies. *J Mol Graph Model*. 2019 Jan;86:43-51. doi: 10.1016/j.jmngm.2018.10.008. Epub 2018 Oct 10. PubMed PMID: 30326373.

14: Korada SK, Yarla NS, Mishra V, Daim MA, Sharma B, Gm A, R R, M P, Peluso I, Kamal MA. Single Probiotic versus Multiple Probiotics - A Debate On Current Scenario for Alleviating Health Benefits. *Curr Pharm Des*. 2018;24(35):4150-4153. doi: 10.2174/1381612824666181012124136. PubMed PMID: 30317991.

15: Lakkakula BVKS, Farran B, Lakkakula S, Peela S, Yarla NS, Bramhachari PV, Kamal MA, Saddala MS, Nagaraju GP. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles. *Semin Cancer Biol*. 2018 Oct 9. pii: S1044-579X(18)30134-2. doi: 10.1016/j.semcancer.2018.09.011. [Epub ahead of print] Review. PubMed PMID: 30314681.

16: Paz MFCJ, Islam MT, Tabrez S, Firoz CK, Jabir NR, Kamal MA, Melo-Cavalcante AAC, Almeida FRC. Effect of Diterpenes on Hepatic System. *Curr Pharm Des*. 2018;24(35):4093-4100. doi: 10.2174/1381612824666181001152247. PubMed PMID: 30277148.

17: Sheikh IA, Yasir M, Khan I, Khan SB, Azum N, Jiffri EH, Kamal MA, Ashraf GM, Beg MA. Lactoperoxidase immobilization on silver nanoparticles enhances its antimicrobial activity. *J Dairy Res*. 2018 Nov;85(4):460-464. doi: 10.1017/S0022029918000730. Epub 2018 Aug 23. PubMed PMID: 30136638.

18: Islam MT, Ali ES, Uddin SJ, Shaw S, Islam MA, Ahmed MI, Chandra Shill M, Karmakar UK, Yarla NS, Khan IN, Billah MM, Pieczynska MD, Zengin G, Malainer C, Nicoletti F, Gulei D, Berindan-Neagoe I, Apostolov A, Banach M, Yeung AWK, El-Demerdash A, Xiao J, Dey P, Yele S, Jóźwik A, Strzałkowska N, Marchewka J, Rengasamy KRR, Horbańczuk J, Kamal MA, Mubarak MS, Mishra SK, Shilpi JA, Atanasov AG. Phytol: A review of biomedical activities. *Food Chem Toxicol*. 2018 Nov;121:82-94. doi: 10.1016/j.fct.2018.08.032. Epub 2018 Aug 18. PubMed PMID: 30130593.

19: Jabir NR, Firoz CK, Bhushan A, Tabrez S, Kamal MA. The Use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview. *Anticancer Agents Med Chem*. 2018;18(1):6-14. doi: 10.2174/1871520616666160520112839. PubMed PMID: 27198985.

20: Alam F, Islam MA, Kamal MA, Gan SH. Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. *Curr Med Chem*. 2018;25(39):5395-5431. doi: 10.2174/0929867323666160813222436. Review. PubMed PMID: 27528060.

21: Rizvi SMD, Hussain T, Ahmed ABF, Alshammari TM, Moin A, Ahmed MQ, Barreto GE, Kamal MA, Ashraf GM. Gold nanoparticles: A plausible tool to combat neurological bacterial infections in humans. *Biomed Pharmacother.* 2018 Nov;107:7-18. doi: 10.1016/j.biopha.2018.07.130. Epub 2018 Jul 31. Review. PubMed PMID: 30075371.

22: Aziz ZAA, Ahmad A, Setapar SHM, Karakucuk A, Azim MM, Lokhat D, Rafatullah M, Ganash M, Kamal MA, Ashraf GM. Essential Oils: Extraction Techniques, Pharmaceutical And Therapeutic Potential - A Review. *Curr Drug Metab.* 2018;19(13):1100-1110. doi: 10.2174/1389200219666180723144850. Review. PubMed PMID: 30039757.

23: Sharma M, Pandey C, Sharma N, Kamal MA, Sayeed U, Akhtar S. Cancer Nanotechnology-An Excursion on Drug Delivery Systems. *Anticancer Agents Med Chem.* 2018;18(15):2078-2092. doi: 10.2174/1871520618666180720164015. PubMed PMID:30033877.

24: Rasool M, Malik A, Alam MZ, Afzal M, Alam R, Arsalan HM, Azam M, Achakzai WM, Saddozai S, Haque A, Alam Q, Asif M, Kamal MA. Optimization of antibacterial activity of ethanolic extracts of *Eucalyptus tereticornis* and *Nigella sativa*: Response surface Methodology. *Pak J Pharm Sci.* 2018 Jul;31(4):1259-1266. PubMed PMID: 30033409.

25: Sheikh IA, Jiffri EH, Ashraf GM, Kamal MA, Beg MA. Structural studies on inhibitory mechanisms of antibiotic, corticosteroid and catecholamine molecules on lactoperoxidase. *Life Sci.* 2018 Aug 15;207:412-419. doi: 10.1016/j.lfs.2018.06.027. Epub 2018 Jun 25. PubMed PMID: 29953881.

26: Niazi ZR, Khan N, Khan S, Alam M, Kamal MA. Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders. *Protein Pept Lett.* 2018;25(7):633-642. doi: 10.2174/0929866525666180614120407. Review. PubMed PMID: 29921193.

27: Sharma N, Sharma M, Shakeel E, Jamal QMS, Kamal MA, Sayeed U, Khan MKA, Siddiqui MH, Arif JM, Akhtar S. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis. *Med Chem.* 2018;14(6):626-640. doi: 10.2174/1573406414666180416125121. PubMed PMID: 29663896.

28: Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA. Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer. *Curr Drug Metab.* 2018;19(9):793-797. doi:

10.2174/1389200219666180416161846. PubMed PMID: 29663879.

29: Akhtar T, Wani WY, Kamal MA, Kaur R. Role of Angiogenic Growth Factors in Psoriasis: A Review. *Curr Drug Metab.* 2018;19(11):910-916. doi: 10.2174/1389200219666180416162942. Review. PubMed PMID: 29663878.

30: Khan H, Marya, Amin S, Kamal MA, Patel S. Flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects. *Biomed Pharmacother.* 2018 May;101:860-870. doi: 10.1016/j.biopha.2018.03.007. Epub 2018 Mar 22. Review. PubMed PMID: 29635895.

31: Singh M, Hussain T, Firdous H, Shaikh S, Rizvi SMD, Moin A, Khan M, Kamal MA. Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review. *Curr Drug Metab.* 2018;19(12):1002-1011. doi: 10.2174/1389200219666180330125003. Review. PubMed PMID: 29600757.

32: Adil M, Iqbal W, Adnan F, Wazir S, Khan I, Khayam MU, Kamal MA, Ahmad S, Ahmed J, Khan IN. Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions? *Curr Drug Metab.* 2018;19(11):902-909. doi: 10.2174/1389200219666180329124130. Review. PubMed PMID: 29595104.

33: Miya Shaik M, Tamargo IA, Abubakar MB, Kamal MA, Greig NH, Gan SH. The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. *Genes (Basel).* 2018 Mar 21;9(4). pii: E174. doi: 10.3390/genes9040174. Review. PubMed PMID: 29561798; PubMed Central PMCID: PMC5924516.

34: Batool A, Kamal MA, Rizvi SMD, Rashid S. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease. *Curr Drug Metab.* 2018;19(8):704-713. doi: 10.2174/1389200219666180305152553. Review. PubMed PMID: 29512457.

35: Hussain T, Bajpai S, Saeed M, Moin A, Alafnan A, Khan M, Kamal MA, Ganash M, Ashraf GM. Potentiating Effect of Ethnomedicinal Plants Against Proliferation on Different Cancer Cell Lines. *Curr Drug Metab.* 2018;19(7):584-595. doi: 10.2174/1389200219666180305144841. Review. PubMed PMID: 29512451.

36: Azhar A, Ashraf GM, Zia Q, Ansari SA, Perveen A, Hafeez A, Saeed M, Kamal MA, Alexiou A, Ganash M, Yarla NS, Baeesa SS, Alfiky MM, Bajouh OS. Frontier View on Nanotechnological Strategies for Neuro-therapy. *Curr Drug Metab.* 2018;19(7):596-604. doi: 10.2174/1389200219666180305144143. Review. PubMed PMID: 29512448.

37: Saeed M, Alshammari FD, Alam MJ, Sarim KM, Ahmad K, Hussain T, Khan M, Kamal MA, Kausar MA, Alkreathy HM, Faisal SM, Ashraf GM. A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer. *Curr Drug Metab*. 2018;19(9):798-805. doi: 10.2174/1389200219666180302160317. Review. PubMed PMID: 29512446.

38: Islam MT, Tabrez S, Jabir NR, Ali M, Kamal MA, da Silva Araujo L, De Oliveira Santos JV, Da Mata AMOF, De Aguiar RPS, de Carvalho Melo Cavalcante AA. An Insight into the Therapeutic Potential of Major Coffee Components. *Curr Drug Metab*. 2018;19(6):544-556. doi: 10.2174/1389200219666180302154551. Review. PubMed PMID: 29512445.

39: Islam A, Kamal MA. Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management. *Endocr Metab Immune Disord Drug Targets*. 2018 Feb 13;18(2):96-97. doi: 10.2174/187153031802180213144657. PubMed PMID: 29508678.

40: Khan H, Zafar M, Den-Haan H, Perez-Sanchez H, Kamal MA. In-silico Studies of Isolated Phytoalkaloid Against Lipoxygenase: Study Based on Possible Correlation. *Comb Chem High Throughput Screen*. 2018;21(3):215-221. doi: 10.2174/1386207321666180220125406. PubMed PMID: 29468959.

41: Khan H, Jawad M, Kamal MA, Baldi A, Xiao J, Nabavi SM, Daglia M. Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future. *Food Chem Toxicol*. 2018 Sep;119:355-367. doi: 10.1016/j.fct.2018.02.014. Epub 2018 Feb 12. Review. PubMed PMID: 29448091.

42: Shakeel E, Arora D, Jamal QMS, Akhtar S, Khan MKA, Kamal MA, Siddiqui MH, Lohani M, Arif JM. Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management. *Curr Drug Metab*. 2018;19(6):523-543. doi: 10.2174/1389200218666170221105402. Review. PubMed PMID: 28228080.

43: Reale M, D'Angelo C, Costantini E, Di Nicola M, Yarla NS, Kamal MA, Salvador N, Perry G. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid- β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. *J Alzheimers Dis*. 2018;62(1):467-476. doi: 10.3233/JAD-170999. PubMed PMID: 29439355; PubMed Central PMCID: PMC5817902.

44: Ahmad F, Siddiqui A, Kamal MA, Sohrab SS. Inhibition of Neurogenesis by Zika Virus Infection. *CNS Neurol Disord Drug Targets*. 2018;17(2):78-86. doi: 10.2174/1871527317666180202115114. PubMed PMID: 29422006.

45: Islam MT, Ali ES, Uddin SJ, Islam MA, Shaw S, Khan IN, Saravi SSS, Ahmad S,

Rehman S, Gupta VK, Găman MA, Găman AM, Yele S, Das AK, de Castro E Sousa JM, de Moura Dantas SMM, Rolim HML, de Carvalho Melo-Cavalcante AA, Mubarak MS, Yarla NS, Shilpi JA, Mishra SK, Atanasov AG, Kamal MA. Andrographolide, a diterpene lactone from *Andrographis paniculata* and its therapeutic promises in cancer. *Cancer Lett.* 2018 Apr 28;420:129-145. doi: 10.1016/j.canlet.2018.01.074. Epub 2018 Feb 14. PubMed PMID: 29408515.

46: Ashraf GM, Azhar A, Zia Q, Ali A, Rehan M, Owais M, Alexiou A, Rauf A, Ganash M, Kamal MA, Rajeh N. Relationship between CNS and Immunology: Correlation with Psychology. *Curr Drug Metab.* 2018;19(10):847-855. doi: 10.2174/1389200219666180129142534. Review. PubMed PMID: 29380699.

47: Islam MA, Khandker SS, Alam F, Kamal MA, Gan SH. Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. *Autoimmun Rev.* 2018 Mar;17(3):226-243. doi: 10.1016/j.autrev.2017.10.014. Epub 2018 Jan 19. Review. PubMed PMID: 29355608.

48: Iman K, Mirza MU, Mazhar N, Vanmeert M, Irshad I, Kamal MA. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease. *CNS Neurol Disord Drug Targets.* 2018 Apr 26;17(1):54-68. doi: 10.2174/1871527317666180115162422. PubMed PMID: 29336270.

49: Khan H, Rengasamy KRR, Pervaiz A, Nabavi SM, Atanasov AG, Kamal MA. Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation. *Eur J Med Chem.* 2018 Jun 10;153:2-28. doi: 10.1016/j.ejmech.2017.12.059. Epub 2017 Dec 23. Review. PubMed PMID: 29329790.

50: Siddiqui I, Erreni M, Kamal MA, Porta C, Marchesi F, Pesce S, Pasqualini F, Schiarea S, Chiabrando C, Mantovani A, Allavena P. Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. *Oncoimmunology.* 2017 Nov 1;7(2):e1388485. doi: 10.1080/2162402X.2017.1388485. eCollection 2018. PubMed PMID: 29308316; PubMed Central PMCID: PMC5749654.

51: Batool S, Noureen N, Kamal MA. Structure Activity Relationship of Venom Toxins Targeting Potassium Channels. *Curr Drug Metab.* 2018;19(8):714-720. doi: 10.2174/1389200219666171227205009. Review. PubMed PMID: 29283069.

52: Khan H, Pervaiz A, Kamal MA, Patel S. Antiplatelet Potential of Plant-Derived Glycosides as Possible Lead Compounds. *Curr Drug Metab.* 2018;19(10):856-862. doi: 10.2174/1389200219666171227204552. Review. PubMed PMID: 29283063.

53: Jabir NR, Anwar K, Firoz CK, Oves M, Kamal MA, Tabrez S. An overview on the current status of cancer nanomedicines. *Curr Med Res Opin.* 2018 May;34(5):911-921. doi: 10.1080/03007995.2017.1421528. Epub 2018 Jan 22. PubMed PMID: 29278015.

54: Putta S, Yarla NS, Kumar K E, Lakkappa DB, Kamal MA, Scotti L, Scotti MT, Ashraf GM, Rao BSB, D SK, Reddy GV, Tarasov VV, Imandi SB, Aliev G. Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications. *Curr Med Chem.* 2018;25(39):5347-5371. doi: 10.2174/0929867325666171206101945. Review. PubMed PMID: 29210634.

55: Sohrab SS, El-Kafrawy SA, Mirza Z, Kamal MA, Azhar EI. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus. *Curr Pharm Des.* 2018;24(1):62-77. doi: 10.2174/1381612823666171109112307. PubMed PMID: 29119921.

56: Diab-Assaf M, Semaan J, El-Sabban M, Al Jaouni SK, Azar R, Kamal MA, Harakeh S. Inhibition of Proliferation and Induction of Apoptosis by Thymoquinone via Modulation of TGF Family, p53, p21 and Bcl-2 α in Leukemic Cells. *Anticancer Agents Med Chem.* 2018;18(2):210-215. doi: 10.2174/1871520617666170912133054. PubMed PMID: 28901264.

57: Khan H, Khattak S, Mubarak MS, Bawazeer SS, Abu-Izneid T, Kamal MA. Antidepressant Potential of Peptides: New Insights as Future Therapeutic. *CNS Neurol Disord Drug Targets.* 2018 Apr 26;17(1):9-13. doi: 10.2174/1871527316666170731102237. PubMed PMID: 28758584.

58: Harakeh S, Khalife J, Baydoun E, Azar R, Al-Hejin A, Barbour E, Azhar E, Niedzwiecki A, Al Jaouni S, Diab-Assaf M, Kamal MA, Rath M. Effects of Ascorbic Acid on Tax, NF- κ B and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes. *Anticancer Agents Med Chem.* 2018;18(2):237-244. doi: 10.2174/1871520617666170725160628. PubMed PMID: 28745235.

2017:

1: Kamal MA. Editorial: Frontier View on Drug Discoveries for Different Diseases - Volume 3. *Curr Drug Metab.* 2017;18(9):784-785. doi: 10.2174/138920021809171226164602.

2: Batool S, Noureen N, Kamal MA. Structure Activity Relationship of Venom Toxins Targeting Potassium Channels. *Curr Drug Metab.* 2017 Dec 27. doi: 10.2174/1389200219666171227205009.

3: Khan H, Pervaiz A, Kamal MA, Patel S. Antiplatelet potential of plant-derived

glycosides as possible lead compounds. *Curr Drug Metab.* 2017 Dec 27. doi: 10.2174/1389200219666171227204552.

4: Jabir NR, Anwar K, Firoz CK, Oves M, Kamal MA, Tabrez S. An overview on the current status of cancer nanomedicines. *Curr Med Res Opin.* 2017 Dec 26:1-22. doi: 10.1080/03007995.2017.1421528.

5: Baig MH, Adil M, Khan R, Dhadi S, Ahmad K, Rabbani G, Bashir T, Imran MA, Husain FM, Lee EJ, Kamal MA, Choi I. Enzyme targeting strategies for prevention and treatment of cancer: Implications for cancer therapy. *Semin Cancer Biol.* 2017 Dec 14. pii: S1044-579X(17)30101-3. doi: 10.1016/j.semcancer.2017.12.003.

6: Solayman M, Islam MA, Alam F, Khalil MI, Kamal MA, Gan SH. Natural Products Combating Neurodegeneration: Parkinson's Disease. *Curr Drug Metab.* 2017;18(1):50-61. doi: 10.2174/1389200217666160709204826.

7: Putta S, Yarla NS, Kumar EK, Lakkappa DB, Kamal MA, Scotti L, Scotti MT, Ashraf GM, Barreto GE, Rao BSB, Kumari DS, Reddy GV, Tarasov VV, Imandi SB, Aliev G. Preventive and Therapeutic potentials of Anthocyanins in diabetes and associated complications. *Curr Med Chem.* 2017 Dec 5. doi: 10.2174/0929867325666171206101945.

8: Sohrab SS, El-Kafrawy SA, Mirza Z, Kamal MA, Azhar EI. Design and delivery of therapeutic siRNAs: application to MERS-Coronavirus. *Curr Pharm Des.* 2017 Nov 8. doi: 10.2174/1381612823666171109112307.

9: Sheikh IA, Jiffri EH, Kamal MA, Ashraf GM, Beg MA. Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer. *Anticancer Res.* 2017 Nov;37(11):6415-6420. PubMed PMID: 29061827.

10: Kamal MA, Greig NH. Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives. *Curr Alzheimer Res.* 2017;14(11):1138-1139. doi: 10.2174/156720501411171006122827.

11: de Oliveira Filho JWG, Islam MT, Ali ES, Uddin SJ, Santos JVO, de Alencar MVOB, Júnior ALG, Paz MFCJ, de Brito MDRM, E Sousa JMC, Shaw S, de Medeiros MDGF, Dantas SMMM, Rolim HML, Ferreira PMP, Kamal MA, Pieczynska MD, Das N, Gupta VK, Mocan A, Dos Santos Andrade TJA, Singh BN, Mishra SK, Atanasov AG, Melo-Cavalcante AAC. A comprehensive review on biological properties of citrinin. *Food Chem Toxicol.* 2017 Dec; 110:130-141. doi: 10.1016/j.fct.2017.10.002.

12: Assaf MD, Semaan J, El-Sabban M, Al-Jaouni SK, Azar R, Kamal MA, Harakeh S. Inhibition of proliferation and induction of Apoptosis by Thymoquinone via modulation of TGF family, p53, p21 and Bcl-2 α in leukemic cells. *Anticancer Agents Med Chem.* 2017 Sep 12. doi: 10.2174/1871520617666170912133054.

13: Kamal MA. Editorial: Frontier View on Drug Discoveries for Different Diseases - Part II. *Curr Drug Metab.* 2017;18(2):88-89. doi: 10.2174/138920021802170321222741.

- 14: Batool S, Nawaz MS, Mushtaq G, Parvaiz F, Kamal MA. In silico analysis of glycinamide ribonucleotide transformylase inhibition by PY873, PY899 and DIA. *Saudi J Biol Sci.* 2017 Sep;24(6):1155-1161. doi: 10.1016/j.sjbs.2014.11.008. Epub 2014 Nov 22. PubMed PMID: 28855807; PubMed Central PMCID: PMC5562383.
- 15: Putta S, Peluso I, Yarla NS, Kilari EK, Bishayee A, Lu DY, Barreto GE, Ashraf GM, Scotti L, Scotti MT, Singla RK, Alexiou T, Atanasov AG, Tarasov VV, Bramhachari PV, Imandi SB, Chintala M, Sharma B, Reale M, Filosa R, Aliev G, Kamal MA. Diabetes mellitus and male aging: Pharmacotherapeutics and clinical implications. *Curr Pharm Des.* 2017 Aug 22. doi: 10.2174/1381612823666170823103830.
- 16: Islam MA, Alam F, Kamal MA, Gan SH, Sasongko TH, Wong KK. Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis. *Front Aging Neurosci.* 2017 Aug 2;9:250. doi: 10.3389/fnagi.2017.00250. eCollection 2017.
- 17: Rayavarapu S, Yarla NS, Kadiri SK, Bishayee A, Vidavalur S, Tadikonda R, Basha M, Pidugu VR, Dowluru KSVGK, Lakappa DB, Kamal MA, Md Ashraf G, Tarasov VV, Chubarev VN, Klochkov SG, Barreto GE, Bachurin SO, Aliev G. Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities. *Sci Rep.* 2017 Aug 16;7(1):8309. doi: 10.1038/s41598-017-05832-w.
- 18: Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, Dermanovic-Dobrota V, Grünblatt E, Jellinger KA, Kamal MA, Kamal W, Leszek J, Sheldrick-Michel TM, Mushtaq G, Meglic B, Natovich R, Pirtosek Z, Rakusa M, Salkovic-Petrisic M, Schmidt R, Schmitt A, Sridhar GR, Vécsei L, Wojszel ZB, Yaman H, Zhang ZG, Cukierman-Yaffe T. The diabetic brain and cognition. *J Neural Transm (Vienna).* 2017 Nov;124(11):1431-1454. doi: 10.1007/s00702-017-1763-2. Epub 2017 Aug 1. Review.
- 19: Khan H, Khattak S, Mubarak MS, Bawazeer SS, Abu-Izneid T, Kamal MA. Antidepressant potential of peptides: New insights as future therapeutic. *CNS Neurol Disord Drug Targets.* 2017 Jul 31. doi: 10.2174/1871527316666170731102237.
- 20: Alam Q, Alam MZ, Sait KHW, Anfinan N, Noorwali AW, Kamal MA, Khan MSA, Haque A. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases. *Curr Drug Metab.* 2017;18(9):868-876. doi: 10.2174/1389200218666170728115606.
- 21: Harakeh S, Khalife J, Baydoun E, Azar R, Al-Hejin A, Barbour E, Azhar E, Niedzwiecki A, Al Jaouni S, Diab-Assaf M, Kamal MA, Rath M. Effects of Ascorbic Acid on Tax, NF- κ B and MMP-9 in Human T-cell Lymphotropic virus type 1 positive malignant T-Lymphocytes. *Anticancer Agents Med Chem.* 2017 Jul 25. doi: 10.2174/1871520617666170725160628.
- 22: Putta S, Yarla NS, Peluso I, Tiwari DK, Reddy GV, Giri PV, Kumar N, Malla R, Chari VB, Reddy D RS, Bade R, Mannarapu M, Barretto G, Lu DY, Tarasov VV,

- Chubarev VN, Ribeiro FF, Scotti L, Scotti MT, Kamal MA, Aliev G, Rao CV, Perry G, Bishayee A. Anthocyanins: Possible role as Multitarget therapeutic agents for prevention and therapy of chronic diseases. *Curr Pharm Des.* 2017 May 19. doi: 10.2174/1381612823666170519151801.
- 23: Kamal MA, Greig NH. Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases. *Curr Pharm Des.* 2017;23(11):1571-1574. doi: 10.2174/1381612823999170201155228.
- 24: Sohrab SS, Suhail M, Kamal MA, Husen A, Azhar EI. Recent Development and Future Prospects of Plant-Based Vaccines. *Curr Drug Metab.* 2017;18(9):831-841. doi: 10.2174/1389200218666170711121810.
- 25: Khan H, Patel S, Kamal MA. Pharmacological and Toxicological Profile of Harmane- β -Carboline Alkaloid: Friend or Foe. *Curr Drug Metab.* 2017;18(9):853-857. doi: 10.2174/1389200218666170607100947.
- 26: Shoaib M, Kamal MA, Rizvi SMD. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease. *Curr Drug Metab.* 2017;18(9):842-852. doi: 10.2174/1389200218666170607101622
- 27: Gupta GK, Kamal MA. EDITORIAL: Current Views on Neurodegeneration: Computational to Clinical Research. *Curr Top Med Chem.* 2017;17(12):1319. doi: 10.2174/156802661712170327212730.
- 28: Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT, Greig NH, Midoux P, Pichon C, Kamal MA. Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective. *Curr Alzheimer Res.* 2017;14(11):1164-1181. doi: 10.2174/1567205014666170508121031.
- 29: Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A. Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals. *Adv Protein Chem Struct Biol.* 2017;108:33-57. doi: 10.1016/bs.apcsb.2017.02.001.
- 30: Jabir NR, Firoz CK, Ahmed F, Kamal MA, Hindawi S, Damanhoury GA, Almehdar HA, Tabrez S. Reduction in CD16/CD56 and CD16/CD3/CD56 Natural Killer Cells in Coronary Artery Disease. *Immunol Invest.* 2017 Jul;46(5):526-535. doi: 10.1080/08820139.2017.1306866.
- 31: Ahmad SS, Akhtar S, Danish Rizvi SM, Kamal MA, Sayeed U, Khan MKA, Siddiqui MH, Arif JM. Screening and Elucidation of Selected Natural Compounds for Anti-Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study. *Curr Comput Aided Drug Des.* 2017 Nov 10;13(4):311-318. doi: 10.2174/1573409913666170414123825.
- 32: Alexiou A, Mantzavinos VD, Greig NH, Kamal MA. A Bayesian Model for the Prediction and Early Diagnosis of Alzheimer's Disease. *Front Aging Neurosci.* 2017 Mar 31;9:77. doi: 10.3389/fnagi.2017.00077. eCollection 2017. PubMed PMID: 28408880;

- 33: Ghaffar A, Batool S, Mushtaq G, Kamal MA. In silico Analysis of AMP-Activated Protein Kinase and Ligand-based Virtual Screening for Identification of Novel AMPK Activators. *Curr Comput Aided Drug Des.* 2017 Mar 9. doi: 10.2174/1573409913666170309144722.
- 34: Al Jaouni SK, Al Muhayawi MS, Hussein A, Elfiki I, Al-Raddadi R, Al Muhayawi SM, Almasaudi S, Kamal MA, Harakeh S. Effects of Honey on Oral Mucositis among Pediatric Cancer Patients Undergoing Chemo/Radiotherapy Treatment at King Abdulaziz University Hospital in Jeddah, Kingdom of Saudi Arabia. *Evid Based Complement Alternat Med.* 2017;2017:5861024. doi: 10.1155/2017/5861024.
- 35: Almasaudi SB, Abbas AT, Al-Hindi RR, El-Shitany NA, Abdel-Dayem UA, Ali SS, Saleh RM, Al Jaouni SK, Kamal MA, Harakeh SM. Manuka Honey Exerts Antioxidant and Anti-Inflammatory Activities That Promote Healing of Acetic Acid-Induced Gastric Ulcer in Rats. *Evid Based Complement Alternat Med.* 2017;2017:5413917. doi: 10.1155/2017/5413917.
- 36: Anilkumar K, Reddy GV, Azad R, Yarla NS, Dharmapuri G, Srivastava A, Kamal MA, Pallu R. Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of *Pueraria tuberosa*. *Oxid Med Cell Longev.* 2017;2017:5498054. doi: 10.1155/2017/5498054. Epub 2017 Jan 24.
- 37: Shakeel E, Arora D, Jamal QM, Akhtar S, Khan MK, Kamal MA, Siddiqui MH, Lohani M, Arif JM. Marine drugs: A hidden wealth and a new epoch for cancer management. *Curr Drug Metab.* 2017 Feb 20. doi: 10.2174/1389200218666170221105402.
- 38: Kamal MA, Shakil S, Nawaz MS, Yu QS, Tweedie D, Tan Y, Qu X, Greig NH. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. *CNS Neurol Disord Drug Targets.* 2017;16(7):820-827. doi: 10.2174/1871527316666170207160606.
- 39: Muteeb G, Rehman MT, Ali SZ, Al-Shahrani AM, Kamal MA, Ashraf GM. Phage Display Technique: A Novel Medicinal Approach to Overcome Antibiotic Resistance by Using Peptide-Based Inhibitors Against β -Lactamases. *Curr Drug Metab.* 2017;18(2):90-95. doi: 10.2174/1389200217666160727100434.
- 40: Ahmad K, Baig MH, Mushtaq G, Kamal MA, Greig NH, Choi I. Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. *Curr Alzheimer Res.* 2017;14(11):1190-1197. doi: 10.2174/1567205014666170203141151.
- 41: Islam BU, Zaidi SK, Kamal MA, Tabrez S. Exploration of Various Proteins for the Treatment of Alzheimer's Disease. *Curr Drug Metab.* 2017;18(9):808-813. doi: 10.2174/1389200218666170203110135.
- 42: Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal MA, Haider N, Midoux P, Pichon C. Bile Salt Stabilized Vesicles (Bilosomes): A Novel Nano-Pharmaceutical Design for Oral Delivery of Proteins and Peptides. *Curr Pharm*

Des. 2017;23(11):1575-1588. doi: 10.2174/1381612823666170124111142.

43: Ahmad I, Khan H, Gilani AU, Kamal MA. Potential of Plant Alkaloids as Antipyretic Drugs of Future. *Curr Drug Metab.* 2017;18(2):138-144. doi: 10.2174/1389200218666170116102625.

44: Kheirandish M, Mahboobi H, Yazdanparast M, Kamal MA. Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients. *Curr Drug Metab.* 2017;18(2):157-162. doi: 10.2174/1389200218666170116105023.

45: Sohrab SS, Kamal MA, Atkinson RL, Alawi MM, Azhar EI. Viral Infection and Obesity: Current Status and Future Prospective. *Curr Drug Metab.* 2017;18(9):798-807. doi: 10.2174/1389200218666170116110443.

46: Ahmad V, Jamal QMS, Siddiqui MU, Shukla AK, Alzohairy MA, Al Karaawi MA, Kamal MA. Methods of Screening-Purification and Antimicrobial Potentialities of Bacteriocin in Health Care. *Curr Drug Metab.* 2017;18(9):814-830. doi: 10.2174/1389200218666170116111309.

47: Sarkar A, Fatima I, Jamal QMS, Sayeed U, Khan MKA, Akhtar S, Kamal MA, Farooqui A, Siddiqui MH. Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier. *Curr Drug Metab.* 2017;18(2):129-137. doi: 10.2174/1389200218666170113125132.

48: Jabir NR, Firoz CK, Kamal MA, Damanhoury GA, Alama MN, Alam Q, Haque A, Almehdar HA, Tabrez S. Assessment of IL-18 Serum Level and Its Promoter Polymorphisms in the Saudi Coronary Artery Disease (CAD) Patients. *J Cell Biochem.* 2017 Jul;118(7):1849-1854. doi: 10.1002/jcb.25870.

49: Islam MA, Alam F, Wong KK, Kamal MA, Gan SH. Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies. *Curr Vasc Pharmacol.* 2017;15(4):313-326. doi: 10.2174/1570161115666170105120931.

50: Jabir NR, Firoz CK, Ashraf GM, Zaidi SK, Shakil S, Kamal MA, Tabrez S. Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease. *Curr Vasc Pharmacol.* 2017;15(4):365-373. doi: 10.2174/1570161115666170105125034.

51: Islam MA, Khandker SS, Alam F, Khalil MI, Kamal MA, Gan SH. Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature. *Curr Top Med Chem.* 2017;17(12):1408-1428. doi: 10.2174/1568026617666170103163054. Review.

52: Ul Islam B, Khan MS, Jabir NR, Kamal MA, Tabrez S. Elucidating Treatment of Alzheimer's Disease via Different Receptors. *Curr Top Med Chem.* 2017;17(12):1400-1407. doi: 10.2174/1568026617666170103163715. Review.

53: Alam MZ, Alam Q, Kamal MA, Jiman-Fatani AA, Azhar EI, Khan MA, Haque A. Infectious Agents and Neurodegenerative Diseases: Exploring the Links. *Curr Top Med Chem.* 2017;17(12):1390-1399. doi: 10.2174/1568026617666170103164040. Review.

54: Hassan W, Noreen H, Rehman S, Gul S, Kamal MA, Kamdem JP, Zaman B, da Rocha

JBT. Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants. *Curr Top Med Chem.* 2017;17(12):1336-1370. doi: 10.2174/1568026617666170102125648. Review.

55: Bhat SA, Kamal MA, Yarla NS, Ashraf GM. Synopsis on Management Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development. *Curr Top Med Chem.* 2017;17(12):1371-1378. doi: 10.2174/1568026616666161222121229. Review.

56: Khan MY, Khan IN, Farman M, Al Karim S, Qadri I, Kamal MA, Al Ghamdi K, Harakeh S. HTLV-1 Associated Neurological Disorders. *Curr Top Med Chem.* 2017;17(12):1320-1330. doi: 10.2174/1568026616666161222141318. Review.

57: Kamal MA. Editorial: Frontier View on Drug Discoveries for Different Diseases - Part I. *Curr Drug Metab.* 2017;18(1):3-4. doi: 10.2174/138920021801170119203152.

58: Rasool M, Malik A, Hussain M, Haq KA, Butt K, Ashraf MAB, Naseer MI, Asif M, Shaikh R, Mustafa MZ, Alam Q, Rasool G, Ahmad W, Haque A, Kamal MA. DARPins Bioengineering and its Theranostic Approaches: Emerging Trends in Protein Engineering. *Curr Pharm Des.* 2017;23(11):1610-1615. doi: 10.2174/1381612822666161208121829.

59: Hoseinzadeh E, Makhdoumi P, Taha P, Hossini H, Stelling J, Kamal MA, Ashraf GM. A Review on Nano-Antimicrobials: Metal Nanoparticles, Methods and Mechanisms. *Curr Drug Metab.* 2017;18(2):120-128. doi: 10.2174/1389200217666161201111146.

60: Shah AA, Dar TA, Dar PA, Ganie SA, Kamal MA. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors. *Curr Drug Metab.* 2017;18(2):96-111. doi: 10.2174/1389200218666161123122734.

61: Asiful Islam M, Alam F, Kamal MA, Gan SH, Wong KK, Sasongko TH. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders. *Curr Pharm Des.* 2017;23(11):1598-1609. doi: 10.2174/1381612823666161122142950.

62: Jabir NR, Firoz CK, Kamal MA, Damanhour GA, Alama MN, Alzahrani AS, Almehdar HA, Tabrez S. Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients. *J Clin Lab Anal.* 2017 Sep;31(5). doi: 10.1002/jcla.22092.

63: Sarkar S, Osama K, Jamal QMS, Kamal MA, Sayeed U, Khan MKA, Siddiqui MH, Akhtar S. Advances and Implications in Nanotechnology for Lung Cancer Management. *Curr Drug Metab.* 2017;18(1):30-38. doi: 10.2174/1389200218666161114142646.

64: Sharma N, Akhtar S, Jamal QMS, Kamal MA, Khan MKA, Siddiqui MH, Sayeed U. Elucidation of Antiangiogenic Potential of Vitexin Obtained from *Cucumis sativus* Targeting Hsp90 Protein: A Novel Multipathway Targeted Approach to Restrain Angiogenic Phenomena. *Med Chem.* 2017;13(3):282-291. doi: 10.2174/1573406413666161111152720.

65: Bibi F, Faheem M, Azhar EI, Yasir M, Alvi SA, Kamal MA, Ullah I, Naseer MI. Bacteria From Marine Sponges: A Source of New Drugs. *Curr Drug Metab.* 2017;18(1):11-15. doi: 10.2174/1389200217666161013090610.

66: Aziz ZABA, Ahmad A, Mohd-Setapar SH, Hassan H, Lokhat D, Kamal MA, Ashraf GM. Recent Advances in Drug Delivery of Polymeric Nano-Micelles. *Curr Drug Metab.* 2017;18(1):16-29. doi: 10.2174/1389200217666160921143616.

67: Jabir NR, Firoz CK, Khan MS, Zaidi SK, Ashraf GM, Shakil S, Kamal MA, Tabrez S. Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome. *Curr Drug Metab.* 2017;18(1):62-68. doi: 10.2174/1389200217666160810155055.

2016

1: Bhat SA, Kamal MA, Ashraf GM. Synopsis on Managing Strategies for Neurodegenerative Disorders: Challenges from Bench to Bedside in Successful Drug Discovery and Development. *Curr Top Med Chem.* 2016 Dec 22.

2: Khan MY, Khan IN, Farman M, Al Karim S, Qadri I, Kamal MA, Al Ghamdi K, Harakeh S. HTLV-1 Associated Neurological Disorders. *Curr Top Med Chem.* 2016 Dec 22.

3: Kamal MA. Editorial: Frontier View on Drug Discoveries for Different Diseases. *Curr Drug Metab.* 2016 Dec 22.

4: Peng F, Guo X, Li Z, Li C, Wang C, Lv W, Wang J, Xiao F, Kamal MA, Yuan C. Antimutagenic Effects of Selenium-Enriched Polysaccharides from *Pyracantha fortuneana* through Suppression of Cytochrome P450 1A Subfamily in the Mouse Liver. *Molecules.* 2016 Dec 16;21(12). pii: E1731. doi: 10.3390/molecules21121731.

5: Rasool M, Malik A, Hussain M, Haq KA, Butt K, Basit A, Naseer MI, Asif M, Shaikh R, Mustafa MZ, Alam Q, Rasool G, Ahmad W, Haque AL, Kamal MA. DARPin Bioengineering and its Theranostic Approaches: Emerging Trends in Protein Engineering. *Curr Pharm Des.* 2016 Dec 8.

6: Hoseinzadeh E, Makhdoumi P, Taha P, Stelling J, Hossini H, Kamal MA, Ashraf GM. A review on nano-antimicrobials: metal nanoparticles, methods, and mechanisms. *Curr Drug Metab.* 2016 Dec 1.

7: Shah AA, Dar PA, Ganie SA, Kamal MA, Dar TA. A Current Perspective on the Inhibition of Cholinesterase by Natural and Synthetic Inhibitors. *Curr Drug Metab.* 2016 Nov 23.

8: Islam MA, Alam F, Kamal MA, Gan SH, Wong KK, Sasongko TH. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders. *Curr Pharm Des.* 2016 Nov 22.

9: Yuan C, Wang C, Wang J, Kumar V, Anwar F, Xiao F, Mushtaq G, Liu Y, Kamal MA, Yuan D. Inhibition on the growth of human MDA-MB-231 breast cancer cells in vitro

and tumor growth in a mouse xenograft model by Se-containing polysaccharides from *Pyracantha fortuneana*. *Nutr Res.* 2016 Nov;36(11):1243-1254. doi: 10.1016/j.nutres.2016.09.012.

10: Jabir NR, Firoz CK, Kamal MA, Damanhoury GA, Alama MN, Alzahrani AS, Almehdar HA, Tabrez S. Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients. *J Clin Lab Anal.* 2016 Nov 9. doi: 10.1002/jcla.22092.

11: Sarkar S, Osama K, Jamal QM, Kamal MA, Sayeed U, Khan MK, Siddiqui MH, Akhtar S. Advances and Implications in Nanotechnology for Lung Cancer Management. *Curr Drug Metab.* 2016 Nov 14.

12: Sharma N, Akhtar S, Jamal QM, Kamal MA, Khan MK, Siddiqui MH, Sayeed U. Elucidation of antiangiogenic potential of Vitexin obtained from *Cucumis sativus* targeting Hsp90 protein: A novel multipathway targeted approach to restrain angiogenic phenomena. *Med Chem.* 2016 Nov 11.

13: Kamal MA. Editorial (Thematic Issue: Association of CNS Disorders with Other Health Issues). *CNS Neurol Disord Drug Targets.* 2016;15(10):1201-1202.

14: Bibi F, Faheem M, Azhar EI, Yasir M, Alvi SA, Kamal MA, Ullah I, Nasser MI. Bacteria from marine sponges: A source of new drugs. *Curr Drug Metab.* 2016 Oct 12.

15: Islam MA, Alam F, Solayman M, Khalil MI, Kamal MA, Gan SH. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. *Oxid Med Cell Longev.* 2016;2016:5137431.

16: Zeb H, Khan IN, Munir I, Ramadan WS, Ahmad MA, Hussein D, Kamal MA, Al Karim S. Updates on Therapeutics in Clinical Trials for Spinal Cord Injuries: Key Translational Applications of Human Embryonic Stem Cells-Derived Neural Progenitors. *CNS Neurol Disord Drug Targets.* 2016;15(10):1266-1278.

17: Ahmad SS, Akhtar S, Jamal QM, Rizvi SM, Kamal MA, Khan MK, Siddiqui MH. Multiple Targets for the Management of Alzheimer's Disease. *CNS Neurol Disord Drug Targets.* 2016;15(10):1279-1289.

18: Wilson CM, Mushtaq G, Kamal MA, Terro F. The Role of Endoproteolytic Processing in Neurodegeneration. *CNS Neurol Disord Drug Targets.* 2016;15(10):1222-1230.

19: Islam MA, Alam F, Kamal MA, Wong KK, Sasongko TH, Gan SH. 'Non-Criteria' Neurologic Manifestations of Antiphospholipid Syndrome: A Hidden Kingdom to be Discovered. *CNS Neurol Disord Drug Targets.* 2016;15(10):1253-1265.

20: Javed H, Kamal MA, Ojha S. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics. *CNS Neurol Disord Drug Targets.* 2016;15(10):1240-1252.

- 21: Kamal MA, Greig NH. Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part C)). *Curr Pharm Des.* 2016;22(28):4337-40.
- 22: Aziz ZA, Ahmad A, Mohd-Setapar SH, Hassan H, Kamal MA, Ashraf GM. Recent advances in drug delivery of polymeric nano-micelles. *Curr Drug Metab.* 2016 Sep 21.
- 23: Alam F, Islam MA, Kamal MA, Gan SH. Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development. *Curr Med Chem.* 2016 Aug 13.
- 24: Jabir NR, Firoz CK, Khan MS, Zaidi SK, Ashraf GM, Shakil S, Kamal MA, Tabrez S. Potential linkage between cerebrovascular diseases and metabolic syndrome. *Curr Drug Metab.* 2016 Aug 10.
- 25: Muteeb G, Ali SZ, Al-Shahrani AM, Kamal MA, Rehman MT, Ashraf GM. Phage Display Technique: A Novel Medicinal Approach To Overcome Antibiotic Resistance By Using Peptide-Based Inhibitors Against B-Lactamases. *Curr Drug Metab.* 2016 Jul 27.
- 26: Solayman M, Islam MA, Alam F, Khalil MI, Kamal MA, Gan SH. Natural Products Combating Against Neurodegeneration: Parkinson's Disease. *Curr Drug Metab.* 2016 Jul 9.
- 27: Pervaiz A, Khan R, Anwar F, Mushtaq G, Kamal MA, Khan H. Alkaloids: An Emerging Antibacterial Modality Against Methicillin Resistant *Staphylococcus aureus*. *Curr Pharm Des.* 2016;22(28):4420-4429.
- 28: Ahmad J, Akhter S, Khan MA, Wahajuddin M, Greig NH, Kamal MA, Midoux P, Pichon C. Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. *Curr Pharm Des.* 2016;22(28):4360-73.
- 29: Khan SA, Khan AM, Karim S, Kamal MA, Damanhoury GA, Mirza Z. Panacea seed "Nigella": A review focusing on regenerative effects for gastric ailments. *Saudi J Biol Sci.* 2016 Jul;23(4):542-53. doi: 10.1016/j.sjbs.2014.10.001.
- 30: Rani N, Bharti S, Krishnamurthy B, Bhatia J, Sharma C, Kamal MA, Ojha S, Arya DS. Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise. *Curr Pharm Des.* 2016;22(28):4341-59.
- 31: Jabir NR, Firoz CK, Bhushan A, Tabrez S, Kamal MA. Use of azoles containing natural products in cancer prevention and treatment: An overview. *Anticancer Agents Med Chem.* 2016 May 20.
- 32: Narayan S, Jaiswal AS, Law BK, Kamal MA, Sharma AK, Hromas RA. Interaction between APC and Fen1 during breast carcinogenesis. *DNA Repair (Amst).* 2016 May;41:54-62. doi: 10.1016/j.dnarep.2016.04.003.
- 33: Majeed M, Hussain AI, Chatha SA, Khosa MK, Kamal GM, Kamal MA, Zhang X, Liu

- M. Optimization protocol for the extraction of antioxidant components from *Origanum vulgare* leaves using response surface methodology. *Saudi J Biol Sci.* 2016 May;23(3):389-96. doi: 10.1016/j.sjbs.2015.04.010.
- 34: Sohrab SS, Kamal MA, Ilah A, Husen A, Bhattacharya PS, Rana D. Development of Cotton leaf curl virus resistant transgenic cotton using antisense $\beta C1$ gene. *Saudi J Biol Sci.* 2016 May;23(3):358-62. doi: 10.1016/j.sjbs.2014.11.013.
- 35: Kamal MA, Greig NH. Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B). *Curr Pharm Des.* 2016;22(20):2923-5.
- 36: Kamal MA. Editorial: Medicinal Chemistry: Neurological and Endocrinological Disorders. *Med Chem.* 2016;12(3):202-3.
- 37: Caraci F, Kamal MA. Editorial: Linkage of CNS and Immunology with Psychology: Searching for New Pharmacological Targets. *CNS Neurol Disord Drug Targets.* 2016;15(4):378-80.
- 38: Haque A, Alam Q, Alam MZ, Azhar EI, Sait KH, Anfinan N, Mushtaq G, Kamal MA, Rasool M. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer. *Curr Pharm Des.* 2016;22(20):2947-59.
- 39: Siddiqui AN, Siddiqui N, Khan RA, Kalam A, Jabir NR, Kamal MA, Firoz CK, Tabrez S. Neuroprotective Role of Steroidal Sex Hormones: An Overview. *CNS Neurosci Ther.* 2016 May;22(5):342-50. doi: 10.1111/cns.12538.
- 40: Ojha S, Kurdi A, Sadek B, Kaleem M, Cai L, Kamal MA, Rajesh M. Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy. *Curr Pharm Des.* 2016;22(20):3058-70.
- 41: Khan SA, Khan SA, Narendra AR, Mushtaq G, Zahran SA, Khan S, Kamal MA. Alzheimer's Disease and Autistic Spectrum Disorder: Is there any Association? *CNS Neurol Disord Drug Targets.* 2016;15(4):390-402.
- 42: Karim S, Kamal MA, Iqbal Z, Ansari SA, Rasool M, Al-Qahtani MH, Damanhoury G, Mirza Z. Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders. *CNS Neurol Disord Drug Targets.* 2016;15(4):477-88.
- 43: Ali B, Jamal QM, Shams S, Al-Wabel NA, Siddiqui MU, Alzohairy MA, Al Karaawi MA, Kesari KK, Mushtaq G, Kamal MA. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. *CNS Neurol Disord Drug Targets.* 2016;15(5):624-8.
- 44: Sharma C, Al Kaabi JM, Nurulain SM, Goyal SN, Kamal MA, Ojha S. Polypharmacological Properties and Therapeutic Potential of β -Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise. *Curr Pharm Des.* 2016;22(21):3237-64.

45: Batool S, Mushtaq G, Kamal W, Kamal MA. Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking. *Med Chem.* 2016;12(1):63-73.

46: Weiguo Lao, Xingliang Jin, Yi Tan, Linda Xiao, Matthew P. Padula, David P. Bishop, Brian Reedy, Madeleine Ong, M.A. Kamal and Xianqin Qu. Characterisation of Bone Beneficial Components from Australian Wallaby Bone. *Medicines* 2016, 3, 23; doi:10.3390/medicines3030023.

47: Kamal MA, Greig NH. Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development. *Curr Pharm Des.* 2016;22(5):515-7.

48: Zia Q, Azhar A, Kamal MA, Aliev G, Owais M, Ashraf GM. Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. *Curr Pharm Des.* 2016;22(7):792-803.

49: Dar PA, Singh LR, Kamal MA, Dar TA. Unique Medicinal Properties of *Withania somnifera*: Phytochemical Constituents and Protein Component. *Curr Pharm Des.* 2016;22(5):535-40.

50: Jabir NR, Siddiqui AN, Firoz CK, Ashraf GM, Zaidi SK, Khan MS, Shakil S, Alama MN, Kamal MA, Tabrez S. Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases. *Curr Pharm Des.* 2016;22(5):566-71.

51: Baig MH, Ahmad K, Roy S, Ashraf JM, Adil M, Siddiqui MH, Khan S, Kamal MA, Provaznik I, Choi I. Computer Aided Drug Design: Success and Limitations. *Curr Pharm Des.* 2016;22(5):572-81.

52: Alam Q, Alam MZ, Mushtaq G, Damanhoury GA, Rasool M, Kamal MA, Haque A. Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. *Curr Pharm Des.* 2016;22(5):541-8.

53: Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, Kamal MA, Hamzei E. Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. *Curr Pharm Des.* 2016;22(5):590-4.

54: Mushtaq G, Greig NH, Anwar F, Al-Abbasi FA, Zamzami MA, Al-Talhi HA, Kamal MA. Neuroprotective Mechanisms Mediated by CDK5 Inhibition. *Curr Pharm Des.* 2016;22(5):527-34.

55: Mir R, Karim S, Kamal MA, Wilson CM, Mirza Z. Conotoxins: Structure, Therapeutic Potential and Pharmacological Applications. *Curr Pharm Des.* 2016;22(5):582-9.

56: Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baesa SS, Kamal MA. Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia. *Med Chem.* 2016;12(3):226-37.

57: Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA,

Kamal MA. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease. *Med Chem.* 2016;12(3):217-25.

58: Shukla R, Sharma DC, Baig MH, Bano S, Roy S, Provazník I, Kamal MA. Antioxidant, Antimicrobial Activity and Medicinal Properties of *Grewia asiatica* L. *Med Chem.* 2016;12(3):211-6.

2015

1: Majeed M, Hussain AI, Chatha SA, Khosa MK, Kamal GM, Kamal MA, Zhang X, Liu M. Optimization protocol for the extraction of antioxidant components from *Origanum vulgare* leaves using response surface methodology. *Saudi J Biol Sci.* 2016 May;23(3):389-96.

2: Ali B, Jamal QM, Mir SR, Shams S, Al-Wabel NA, Kamal MA. In silico Analysis for Predicting Fatty Acids of Black Cumin Oil as Inhibitors of P-Glycoprotein. *Pharmacogn Mag.* 2015 Oct;11(Suppl 4):S606-10.

3: Sharma C, Sadek B, Goyal SN, Sinha S, Kamal MA, Ojha S. Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development. *Evid Based Complement Alternat Med.* 2015;2015:238482.

4: Ahmad J, Akhter S, Rizwanullah M, Amin S, Rahman M, Ahmad MZ, Rizvi MA, Kamal MA, Ahmad FJ. Nanotechnology-based inhalation treatments for lung cancer: state of the art. *Nanotechnol Sci Appl.* 2015 Nov 19;8:55-66.

5: El-Aidy WK, Ebeid AA, Sallam Ael-R, Muhammad IE, Abbas AT, Kamal MA, Sohrab SS. Evaluation of propolis, honey, and royal jelly in amelioration of peripheral blood leukocytes and lung inflammation in mouse conalbumin-induced asthma model. *Saudi J Biol Sci.* 2015 Nov;22(6):780-8.

6: Rasool M, Malik A, Manan A, Aziz K, Mahmood A, Zaheer S, Shuja N, Qazi MH, Kamal MA, Karim S. Determination of potential role of antioxidative status and circulating biochemical markers in the pathogenesis of ethambutol induced toxic optic neuropathy among diabetic and non-diabetic patients. *Saudi J Biol Sci.* 2015 Nov;22(6):739-43.

7: Sohrab SS, Bhattacharya PS, Rana D, Kamal MA, Pande MK. Development of interspecific *Solanum lycopersicum* and screening for Tospovirus resistance. *Saudi J Biol Sci.* 2015 Nov;22(6):730-8.

8: Ashraf GM, Tabrez S, Jabir NR, Firoz CK, Ahmad S, Hassan I, Alexiou A, Kamal MA. An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy. *Curr Drug Metab.* 2015;16(8):719-27.

9: Akram ON, Mushtaq G, Kamal MA. An Overview of Current Screening and Management Approaches for Prostate Cancer. *Curr Drug Metab.* 2015;16(8):713-8.

- 10: Soursou G, Alexiou A, Ashraf GM, Siyal AA, Mushtaq G, Kamal MA. Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer's and Parkinson's Disease. *Curr Drug Metab.* 2015;16(8):705-12.
- 11: Kamal MA. Global Trends in Nanotechnological Approaches for Various Health Issues - Volume II. *Curr Drug Metab.* 2015;16(8):598-601.
- 12: Shaikh S, Shakil S, Abuzenadah AM, Rizvi SM, Roberts PM, Mushtaq G, Kamal MA. Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update. *Curr Drug Metab.* 2015;16(5):362-70.
- 13: Ashraf GM, Perveen A, Zaidi SK, Tabrez S, Shakil S, Ahmad A, Haque R, Ahsan J, Kamal MA, Banu N. Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases. *Protein Pept Lett.* 2015;22(11):954-62.
- 14: Kamal MA. Editorial: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1. *Curr Drug Metab.* 2015;16(5):334-5.
- 15: Waqar M, Kamal MA, Batool S. In Silico Analysis of Binding Interaction of Mamba Toxins with M4 and M2 Muscarinic Acetylcholine Receptors for Therapeutic Use in Alzheimer's Disease. *CNS Neurol Disord Drug Targets.* 2015;14(8):1031-40.
- 16: Banu S, Jabir NR, Mohan R, Manjunath NC, Kamal MA, Kumar KR, Zaidi SK, Khan MS, Tabrez S. Correlation of Toll-like receptor 4, interleukin-18, transaminases, and uric acid in patients with chronic periodontitis and healthy adults. *J Periodontol.* 2015 Mar;86(3):431-9.
- 17: Ahmad J, Amin S, Rahman M, Rub RA, Singhal M, Ahmad MZ, Rahman Z, Addo RT, Ahmad FJ, Mushtaq G, Kamal MA, Akhter S. Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics. *Curr Drug Metab.* 2015;16(8):633-44.
- 18: Mushtaq G, Khan JA, Joseph E, Kamal MA. Nanoparticles, Neurotoxicity and Neurodegenerative Diseases. *Curr Drug Metab.* 2015;16(8):676-84.
- 19: Khan S, Rizvi SM, Ahmad V, Baig MH, Kamal MA, Ahmad S, Rai M, Zafar Iqbal AN, Mushtaq G, Khan MS. Magnetic Nanoparticles: Properties, Synthesis and Biomedical Applications. *Curr Drug Metab.* 2015;16(8):685-704.
- 20: Rasool M, Malik A, Manan A, Ansari SA, Asif M, Qazi MH, Kamal MA, Pushparaj PN. Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis. *Curr Drug Metab.* 2015;16(8):602-8.
- 21: Baig MH, Ahmad K, Hasan Q, Khan MK, Rao NS, Kamal MA, Choi I. Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico Approach. *Evid Based Complement Alternat Med.* 2015;2015:497253.

- 22: Yuan C, Li Z, Peng F, Xiao F, Ren D, Xue H, Chen T, Mushtaq G, Kamal MA. Combination of selenium-enriched green tea polysaccharides and Huo-ji polysaccharides synergistically enhances antioxidant and immune activity in mice. *J Sci Food Agric*. 2015 Dec;95(15):3211-7.
- 23: Jabir NR, Firoz CK, Baeesa SS, Ashraf GM, Akhtar S, Kamal W, Kamal MA, Tabrez S. Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. *CNS Neurosci Ther*. 2015 Jan;21(1):1-7.
- 24: Firoz CK, Jabir NR, Kamal MA, Alama MN, Damanhoury GA, Khan W, Alzahrani AS, Almeshdar HA, Tabrez S. Neopterin: An immune biomarker of coronary artery disease and its association with other CAD markers. *IUBMB Life*. 2015 Jun;67(6):453-9.
- 25: Xiao CY, Fu BB, Li ZY, Mushtaq G, Kamal MA, Li JH, Tang GC, Xiao SS. Observations on the expression of human papillomavirus major capsid protein in HeLa cells. *J Periodontol*. 2015 May 23;15:53.
- 26: Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA. Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy. *Curr Drug Metab*. 2015;16(5):346-53.
- 27: Yuan C, Li Z, Yi M, Wang X, Peng F, Xiao F, Chen T, Wang C, Mushtaq G, Kamal MA. Effects of polysaccharides from selenium-enriched *Pyracantha fortuneana* on mice liver injury. *Med Chem*. 2015;11(8):780-8.
- 28: Rasool M, Malik A, Naseer MI, Manan A, Ansari S, Begum I, Qazi MH, Pushparaj P, Abuzenadah AM, Al-Qahtani MH, Kamal MA, Gan S. The role of epigenetics in personalized medicine: challenges and opportunities. *BMC Med Genomics*. 2015;8 Suppl 1:S5.
- 29: Rasool M, Malik A, Manan A, Arooj M, Qazi MH, Kamal MA, Sheikh IA, Gan SH, Asif M, Naseer MI. Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level. *Med Chem*. 2015;11(7):618-28.
- 30: Faheem M, Naseer MI, Chaudhary AG, Kumosani TA, Rasool M, Algahtani HA, Bibi F, Kamal MA, Al-Qahtani MH. Array-comparative genomic hybridization analysis of a cohort of Saudi patients with epilepsy. *CNS Neurol Disord Drug Targets*. 2015;14(4):468-75.
- 31: Siew Hua G, Kamal MA, Lima MM, Khalil MI, Pasupuleti VR, Aliev G. Medicinal plants in management of type 2 diabetes and neurodegenerative disorders. *Evid Based Complement Alternat Med*. 2015;2015:686872.
- 32: Syed Mohd. Danish Rizvi, Sibhghatulla Shaikh, Shah Mohammad Abbas Waseem, Shazi Shakil, Adel M. Abuzenadah, Deboshree Biswas, Shams Tabrez, Ghulam Md. Ashraf, M.A. Kamal (2015) Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. *EXCLI Journal*; 14:684-696.

- 33: Sinha S, Shukla S, Khan S, Farhan M, Kamal MA, Meeran SM. Telomeric Repeat Containing RNA (TERRA): Aging and Cancer. *CNS Neurol Disord Drug Targets*. 2015;14(7):936-46. Review.
- 34: Batool S, Khan ZA, Kamal W, Mushtaq G, Kamal MA. In silico Screening for Identification of Novel Anti-malarial Inhibitors by Molecular Docking, Pharmacophore Modeling and Virtual Screening. *Med Chem*. 2015;11(7):687-700.
- 35: Umar Z, Rasool M, Asif M, Karim S, Malik A, Mushtaq G, Kamal MA, Mansoor A. Evaluation of hemoglobin concentration in pregnancy and correlation with different altitude: a study from balochistan plateau of pakistan. *Open Biochem J*. 2015 Feb 23;9:7-14.
- 36: Kamal MA, Mushtaq G, Greig NH. Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders. *CNS Neurol Disord Drug Targets*. 2015;14(4):492-501. Review.
- 37: Malik IA, Akhter S, Kamal MA. Treatment of psoriasis by using Hijamah: A case report. *Saudi J Biol Sci*. 2015 Jan;22(1):117-21.
- 38: Ashraf GM, Perveen A, Zaidi SK, Tabrez S, Kamal MA, Banu N. Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent. *Saudi J Biol Sci*. 2015 Jan;22(1):112-6.
- 39: Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, Sani S, Qazi MH, Kamal MA, Iqbal Z, Hussain A. Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. *Saudi J Biol Sci*. 2015 Jan;22(1):106-11.
- 40: Mushtaq G, Hussain I, Khan JA, Kamal MA. Lateral meningocele with asymmetric canal stenosis: A case study. *Saudi J Biol Sci*. 2015 Jan;22(1):102-5.
- 41: Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J Biol Sci*. 2015 Jan;22(1):90-101.
- 42: Ashraf GM, Perveen A, Tabrez S, Zaidi SK, Kamal MA, Banu N. Studies on the role of goat heart galectin-1 as a tool for detecting post-malignant changes in glycosylation pattern. *Saudi J Biol Sci*. 2015 Jan;22(1):85-9.
- 43: D'Angelo C, Costantini E, Kamal MA, Reale M. Experimental model for ELF-EMF exposure: Concern for human health. *Saudi J Biol Sci*. 2015 Jan;22(1):75-84.
- 44: Jabbar F, Asif M, Dutani H, Hussain A, Malik A, Kamal MA, Rasool M. Assessment of the role of general, biochemical and family history characteristics in kidney stone formation. *Saudi J Biol Sci*. 2015 Jan;22(1):65-8.
- 45: Shaikh S, Fatima J, Shakil S, Danish Rizvi SM, Kamal MA. Prevalence of multidrug resistant and extended spectrum beta-lactamase producing *Pseudomonas aeruginosa* in a tertiary care hospital. *Saudi J Biol Sci*. 2015 Jan;22(1):62-4.

- 46: Baig SA, Asif M, Irfani TM, Hussain A, Cheema AM, Malik A, Kamal MA, Rasool M. The association of nutritional profile and prognosis of degenerative diseases associated with carbohydrate and lipid metabolism at high altitude of district Ziarat, Pakistan. *Saudi J Biol Sci.* 2015 Jan;22(1):50-5.
- 47: Khan S, Haseeb M, Baig MH, Bagga PS, Siddiqui HH, Kamal MA, Khan MS. Improved efficiency and stability of secnidazole - An ideal delivery system. *Saudi J Biol Sci.* 2015 Jan;22(1):42-9.
- 48: Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Risk factors for acquisition of extended spectrum beta lactamase producing *Escherichia coli* and *Klebsiella pneumoniae* in North-Indian hospitals. *Saudi J Biol Sci.* 2015 Jan;22(1):37-41.
- 49: Banu S, Jabir NR, Manjunath NC, Khan MS, Ashraf GM, Kamal MA, Tabrez S. Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. *Saudi J Biol Sci.* 2015 Jan;22(1):32-6
- 50: Damanhoury GA, Jarullah J, Marouf S, Hindawi SI, Mushtaq G, Kamal MA. Clinical biomarkers in sickle cell disease. *Saudi J Biol Sci.* 2015 Jan;22(1):24-31.
- 51: Firoz CK, Jabir NR, Khan MS, Mahmoud M, Shakil S, Damanhoury GA, Zaidi SK, Tabrez S, Kamal MA. An overview on the correlation of neurological disorders with cardiovascular disease. *Saudi J Biol Sci.* 2015 Jan;22(1):19-23.
- 52: Mushtaq G, Khan JA, Kumosani TA, Kamal MA. Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. *Saudi J Biol Sci.* 2015 Jan;22(1):4-13.
- 53: Kamal MA. Biological aspect of various global health issues. *Saudi J Biol Sci.* 2015 Jan;22(1):1-2.
- 54: Patruno A, Tabrez S, Pesce M, Shakil S, Kamal MA, Reale M. Effects of extremely low frequency electromagnetic field (ELF-EMF) on catalase, cytochrome P450 and nitric oxide synthase in erythro-leukemic cells. *Life Sci.* 2015 Jan 15;121:117-23.
- 55: Ali A, Sheikh IA, Mirza Z, Gan SH, Kamal MA, Abuzenadah AM, Damanhoury GA, Ashraf GM. Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders. *Curr Drug Metab.* 2015;16(5):376-88.
- 56: Rasool M, Malik A, Manan A, Ansari SA, Naseer MI, Qazi MH, Asif M, Gan SH, Kamal MA. Nanoparticle-Based Therapy in Genomics. *Curr Drug Metab.* 2015;16(5):354-61.
- 57: Jabir NR, Tabrez S, Firoz CK, Zaidi SK, Baeesa SS, Gan SH, Shakil S, Kamal MA. A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy:

Present and Future Research Implications. *Curr Drug Metab.* 2015;16(5):336-45.

58: Rasool M, Naseer MI, Malik A, Manan A, Ullah I, Abid NB, Kim MO, Qazi MH, Kamal MA, Bibi F. Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties. *Curr Drug Metab.* 2015;16(5):389-96.

59: Rahman M, Ahmad MZ, Ahmad J, Firdous J, Ahmad FJ, Mushtaq G, Kamal MA, Akhter S. Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues. *Curr Drug Metab.* 2015;16(5):397-409.

60: Mushtaq G, Khan S, Hussain I, Kamal MA (2015) Schwannoma of Lumbar Spine: A Medical Case Study. *Enliven: Neurol Neurotech* 1(1): 001.

61: Javed Ahmad, Sohail Akhter, Md Rizwanullah, Saima Amin, Mahfoozur Rahman, Mohammad Zaki Ahmad, Moshahid Alam Rizvi, M.A. Kamal, Farhan Jalees Ahmad (2015) Nanotechnology-Based Inhalation Treatments for Lung Cancer: State of The Art. *Nanotechnology, Science and Applications*; 8: 1–12.

2014

1. Karim S, Mirza Z, Ansari SA, Rasool M, Iqbal Z, Sohrab SS, **Kamal MA**, Abuzenadah AM, Al-Qahtani MH. (2014) Transcriptomics study of neurodegenerative disease: emphasis on synaptic dysfunction mechanism in Alzheimer's disease. *CNS Neurol Disord Drug Targets.* **13(7)**, 1202-1212.
2. Marcella Reale¹, **M.A. Kamal**, Antonia Patruno, Erica Costantini¹, Chiara D'Angelo, Miko Pesce and Nigel H. Greig (2014) Neuronal cellular responses to extremely low frequency electromagnetic field exposure: Implications regarding oxidative stress and neurodegeneration. *PLoS One*, 15; 9(8): e104973. doi: 10.1371/journal.pone.0104973.
3. Mushtaq G, Khan JA and **M.A. Kamal** (2014) Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus. *CNS Neurol. Disord. Drug Targets*, **13(7)**, 1192-1201.
4. Nawaz MS, Parveen Z, Wang L, Rashid S, Fatmi MQ and **Kamal MA** (2014) Computational Study of Human Tyrosine Hydroxylase Mutants to Uphold [4-(Propan-2-yl) Phenyl]Carbamic Acid as a Potential Inhibitor. *CNS Neurol. Disord. Drug Targets*, **13(7)**, 1169-1174.
5. Chowhan RK, Mittal S, Dar TA, **Kamal MA**, Singh LR. (2014) Ignored Avenues in Alpha-Synuclein Associated Proteopathy. *CNS Neurol Disord Drug Targets.* **13(7)**, 1246-1257.
6. Bibi F, Yasir M, Sohrab SS, Azhar EI, Al-Qahtani MH, Abuzenadah AM, **Kamal MA**, Naseer MI. (2014) Link between Chronic Bacterial Inflammation and Alzheimer Disease. *CNS Neurol Disord Drug Targets.* **13(7)**, 1140-1147.
7. Nurulain SM, Adeghate E, Shamsulislam A, Yasin J, **Kamal MA**, Sharma C, Adem A, Ojha S (2014) Sub-Chronic exposure of no-observable adverse effect dose of terbufos sulfone may cause neuroinflammation in diabetic and non-diabetic rats. *CNS Neurol Disord Drug Targets*, 13(8): 1397-1405.
8. Mirza Z, Pillai VG, **Kamal MA** (2014) Protein Interactions Between the C-terminus of A β -Peptide and Phospholipase A2 - A Structure Biology Based Approach to Identify

- Novel Alzheimer Therapeutics. *CNS Neurol Disord Drug Targets*. **13(7)**, 1224-1231.
9. Karim S, Mirza Z, **Kamal MA**, Abuzenadah AM, Azhar EI, Al-Qahtani MH, Damanhoury GA, Ahmad F, Sohrab SS. (2014) Association of Viruses in Neurodegenerative and Neurobehavioral Diseases. *CNS Neurol Disord Drug Targets*. **13(7)**, 1213-1223.
 10. Shaikh S, Rizvi SM, Hameed N, Biswas D, Khan M, Shakil S, **Kamal MA** (2014) Aptiom (Eslicarbazepine acetate) as a Dual Inhibitor of β -Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. *CNS Neurol Disord Drug Targets*. **13(7)**, 1258-1262.
 11. Khan I, Yasir M, Azhar EI, Kumosani T, Barbour EK, Bibi F, **Kamal MA** (2014) Implication of Gut Microbiota in Human Health. *CNS Neurol Disord Drug Targets*, **13(8)**: 1325-1333.
 12. Karim S, Mirza Z, **Kamal MA**, Abuzenadah AM, Al-Qahtani MH (2014) Gene Expression Analysis Approach to Establish Possible Links between Parkinson's Disease, Cancer and Cardiovascular Diseases. *CNS Neurol Disord Drug Targets*, **13(8)**: 1334-1345.
 13. Hanuma K. Karnati, Manas Panigrahi, Noor A. Shaik, Nigel H. Greig, S. Appala R. Bagadi, Nagaiah Kapalayayi and **Kamal MA** (2014) Down regulated expression of Claudin-1 and Claudin-5 and up regulation of β -Catenin: Association with human glioma progression. *CNS Neurol Disord Drug Targets*. **13(8)**, 1413-1426.
 14. Hasan GM, Sheikh IA, Karim S, Haque A, **Kamal MA**, Chaudhary AG, Azhar E, Mirza Z (2014) Effect of Electromagnetic Radiations on Neurodegenerative Diseases - Technological Revolution as a Curse in Disguise. *CNS Neurol Disord Drug Targets*, **13(8)**: 1406-1412.
 15. **M.A. Kamal** (2014) Linkage of neurodegenerative disorders with other health issues – Volume I. *CNS Neurol. Disord. Drug Targets*, **13(7)**, 1125-1129.
 16. Mushtaq G, Greig NH, Khan JA, **M.A. Kamal** (2014) Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. *CNS Neurol Disord Drug Targets*, **13(8)**:1432-1439.
 17. Ashraf GM, Greig NH, Khan TA, Hassan I, Tabrez S, Shakil S, Sheikh IA, Zaidi SK, Akram M, Jabir NR, Firoz CK, Naeem A, Alhazza IM, Damanhoury GA, **Kamal MA** (2014) Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. *CNS Neurol Disord Drug Targets*; **13(7)**: 1280-1293.
 18. Sayed Sartaj Sohrab, **M.A. Kamal**, Abdul Ilah, Azmal Husen, P.S. Bhattacharya and D. Rana (2014) Development of Cotton leaf curl virus resistant transgenic cotton using antisense β C1 gene. *Saudi J. Biol. Sci.* **21(6)**: 626-31. doi: 10.1016/j.sjbs.2014.11.006.
 19. **M.A. Kamal** (2014) Linkage of neurodegenerative disorders with other health issues – Volume II. *CNS Neurol. Disord. Drug Targets*, **13(8)**: 1310-1314.
 20. Ahmad MZ, Ahmad J, Rahman M, Anwar M, Mallick N, Ahmad FJ, Rahman Z, **Kamal MA**, Akhter S (2014) Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer's Disease. *CNS Neurol Disord Drug Targets* **13(8)**:1315-1324.
 21. Mohd Hassan Baig, Khurshid Ahmad, Mohd Adil, Zainul A Khan, Mohd Imran Khan, Mohtashim Lohani, Mohd Sajid Khan, **M.A. Kamal** (2014) Drug Discovery and *In Silico* Techniques: A Mini-Review. *Enzyme Engineering*, **4(1)**, <http://dx.doi.org/10.4172/2329-6674.1000123> ([40](http://omicsgroup.org/journals/drug-</div><div data-bbox=)

discovery-and-in-silico-techniques-a-minireview-2329-6674-1000123.php?aid=43621

22. Ahmad K, Balaramnavar VM, Baig MH, Srivastava AK, Khan S, **Kamal MA** (2014) Identification of Potent Caspase-3 Inhibitors for Treatment of Multi-Neurodegenerative Diseases using Pharmacophore Modeling and Docking Approaches. *CNS Neurol Disord Drug Targets*, 13(8): 1346-1353.
23. Sayed Sartaj Sohrab, Esam.I.Azhar, **M.A.Kamal**, P.S. Bhattacharya, D. Rana (2014) Genetic variability of Cotton leaf curl Betasatellite in Northern India. *Saudi J. Biol. Sci.*, 21(6), 626-631.
24. Gohar Mushtaq, Jalaluddin A. Khan, **M.A. Kamal** (2014) "Impaired Glucose Metabolism in Alzheimer's Disease and Diabetes" *Enzyme Engineering* Vol. 3, Issue 2 (<http://omicsgroup.org/journals/impaired-glucose-metabolism-in-alzheimers-disease-and-diabetes-2329-6674-1000124.php?aid=49586>) 4:124. doi:10.4172/2329-6674.1000124.
25. Iftikhar H, Ahmad I, Gan SH, Shaik MM, Iftikhar N, Nawaz MS, Greig NH and **M.A. Kamal** (2014) Quinoline derivatives: candidate drugs for a Class B G-protein coupled receptor, the Calcitonin gene-related peptide receptor, a cause of migraines. *CNS Neurol. Disord. Drug Targets*, **13(7)**, 1130-1139.
26. Shaik MM, Lin TH, Gan SH. (2014) Do Folate, Vitamins B6 and B12 Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics. *CNS Neurol. Disord. Drug Targets*. 13(5), 828-835.
27. Nigel H. Grieg, **M.A. Kamal**, Nasimudeen R. Jabir, Shams Tabrez, Faizul H. Nasim, Adel M. Abuzenadah and Gjumrakch Aliev (2014) Specific Cholinesterase Inhibitors: A Potential Tool to Assist in Management of Alzheimer Disease. *Frontiers in Drug Design & Discovery*, Chapter, Pages: 366-386 (21); DOI: 10.2174/9781608058228114060008.
28. Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, Qazi MH, Qazi AM, **Kamal MA**, Gan SH, Sheikh IA (2014) Recent updates in the treatment of neurodegenerative disorders using natural compounds. *Evidence-Based Complementary and Alternative Medicine* (Vol. 2014, Article ID 979730, 7 pages; <http://dx.doi.org/10.1155/2014/979730>).
29. M. Rasool, S. Rashid, M. Arooj, S.A. ANSARI, K.M. Khan, A. Malik, M.I. Naseer, S. Zahid, A. Manan, M. Asif, Z. Razzaq, S. Ashraf, M.H. Qazi, Z. Iqbal, S.H. Gan, **M.A. Kamal** and I.A. Sheikh (2014) New possibilities in hepatocellular carcinoma treatment *Anticancer Res.* 34, 1563-1572.
30. Syed Mohd Danish Rizvi, Shazi Shakil, Mohd Zeeshan, Mohd Sajid Khan, Sibghatulla Shaikh, Deboshree Biswas, Adnan Ahmad, **M.A. Kamal** (2014) An enzoinformatics study targeting polo-like kinases-1 enzyme: Comparative assessment of anticancer potential of compounds isolated from leaves of *Ageratum*

houstonianum. Phcog. Mag. 10:14-21
(<http://www.phcog.com/text.asp?2014/10/37/14/127333>).

31. M. Rasool, J. Iqbal, A. Malik, H. S. Ramzan, S. Qureshi, M. Asif, M. H. Qazi, **M.A. Kamal**, A. G. A. Chaudhary, M. H. AlQahtani, S. H. Gan and S. Karim (2014) Hepatoprotective effects of Silybum Marianum (Silymarin) and Glycyrrhiza Glabra (Glycyrrhizin) in Combination: A Possible Synergy. Evidence-Based Complementary and Alternative Medicine. Vol. 2014, Article ID 641597, 9 pages, <http://dx.doi.org/10.1155/2014/641597>.
32. Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA, Benberin VV, Bachurin SO (2014) Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease. *Curr. Med. Chem.* **21**, 2208-2217.
33. Alam MZ, Alam Q, Jiman-Fatani A, **MA Kamal**, Abuzenadah AM, Chaudhary AG, Akram M, Haque A. (2014) Candida Identification: A Journey from Conventional to Molecular Methods in Medical Mycology. *World J. Microbiol. & Biotechnology* 30 (5):1437-1451; DOI 10.1007/s11274-013-1574-z.
34. Hamidreza Mahboobi, Javad Golmirzaei, Gan SH, Mehrdad Jalalian and **M.A. Kamal** (2014) Humanin: A possible linkage between Alzheimer's disease and type 2 diabetes. *CNS Neurol. Disord. Drug Targets* **13(3)**, 543-553.
35. Mahmood Rasool, Arif Malik, Aamer Qazi, Ishfaq Ahmed Sheikh, Abdul Manan, Sumaira Shaheen, Mahmood Husain Qazi, Adeel Chaudhary, Adel M. Abuzenadah, Muhammad Asif, Mohammed Hussain Alqahtani, Zafar Iqbal, Munvar Miya Shaik, Siew Hua Gan and **M.A. Kamal** (2014) Current view from Alzheimer disease to type 2 diabetes mellitus. *CNS Neurol. Disord. Drug Targets.* **13(3)**, 533-542.
36. **M.A. Kamal** (2014) Current update on association between Alzheimer's disease and Type 2 Diabetes Mellitus – Volume II. *CNS & Neurological Disorders-Drug Targets.* **13(3)**, 377-382 (Editorial).
37. Zeenat Mirza, **MA Kamal**, Adel M Abuzenadah, Mohammed Hussein Al-Qahtani, Sajjad Karim (2014) Establishing genomic/transcriptomic links between Alzheimer's disease and type II diabetes mellitus by meta-analysis approach *CNS & Neurological Disorders-Drug Targets* **13(3)**, 501-516.
38. Sayed Sartaj Sohrab, Sajjad Karim, **MA Kamal**, Adel M Abuzenadah, Adeel Gulzar Chaudhary, Mohammed Hussein Al-Qahtani, Zeenat Mirza (2014) Bacteriophage – A common divergent therapeutic approach for Alzheimer's disease and Type II Diabetes Mellitus. *CNS & Neurological Disorders-Drug Targets.* **13(3)**, 491-500.
39. Syed Mohd. Danish Rizvi, Shahnawaz Shakil, Deboshree Biswas, Shazi Shakil, Sibhghatulla Shaikh, Paramdeep Bagga, **M.A. Kamal** (2014) Invokana (Canagliflozin) as a dual inhibitor of AChE and SGLT2: advancement in Alzheimer's disease-Diabetes type 2 linkage via an enzoinformatics study. *CNS & Neurological Disorders-Drug Targets,* **13(3)**, 447-451.
40. Gjumrakch Aliev, Khan Shahida, Siew Hua Gan, CK Firoz, Aziz Khan, Adel Abuzenadah, Warda Kamal, **M.A. Kamal**, Yi Tan, Xianqin Qu and M. Reale (2014)

- Alzheimer's disease and type 2 Diabetes mellitus: The link to tyrosine hydroxylase and probable nutritional strategies. *CNS & Neurological Disorders-Drug Targets* **13(3)**, 467-477.
41. Qamre Alam, Absarul Haque, Mohammad Zubair Alam, Sajjad Karim, Siew Hua Gan, **M.A. Kamal**, Asif Jiman-Fatani, Ghazi A. Damanhouri Adel M Abuzenadah, Adeel G A Chaudhary (2014) A Nanotechnological Approach in Management of Alzheimer's Diseases and Type 2 diabetes. *CNS & Neurological Disorders-Drug Targets* **13(3)**, 478-486.
 42. Munvar Miya Shaik, S. Ahmad, Siew Hua Gan, Adel M. Abuzenadah, Ejaz Ahmad, Shams Tabrez, Farid Ahmed and **M.A. Kamal** (2014) How do periodontal infections affect the progression of Type 2 Diabetes and Alzheimer's disease? *CNS & Neurological Disorders-Drug Targets* **13(3)**, 460-466.
 43. Syed Sayeed Ahmad, Sibhghatulla Shaikh, Mohd. Afaque Ansari, Shazi Shakil, Syed Mohd. Danish Rizvi, Shahnawaz Shakil, Shams Tabrez, Salman Akhtar, **M.A. Kamal**, Ghazi A. Damanhouri (2014) Prediction of comparative inhibition efficiencies for a novel natural ligand, Galangin against human brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics study. *CNS & Neurological Disorders-Drug Targets* **13(3)**, 452-459.
 44. Aftab Alam, Sibhghatulla Shaikh, Syed Sayeed Ahmad, Shahnawaz Shakil, Syed Mohd. Danish Rizvi, Shazi Shakil, Mohd. Imran, Shams Tabrez, **M.A. Kamal** (2014) Molecular interaction of human brain acetylcholinesterase with a natural inhibitor Huperzine-B: An Enzoinformatics approach. *CNS & Neurological Disorders-Drug Targets* **13(3)**, 487-490.
 45. M.Merad, W.Soufi, S.Ghalem, F.Boukli, M.H. Baig, K. Ahmad and **M.A. Kamal** (2014) Molecular interaction of acetylcholinesterase with carnosic acid derivatives: A neuroinformatics study. *CNS & Neurological Disorders-Drug Targets*. **13(3)**, 440-446.
 46. Anupriya Verma, Saimeen Siddiqui, Syed Sayeed Ahmad, Sibhghatulla Shaikh, Divya Singh, Syed Mohd. Danish Rizvi, Shazi Shakil, Mohd. Haris Siddiqui, Shahnawaz, S. Shakil, Shams Tabrez, **M.A. Kamal** (2014) Current acetylcholinesterase-inhibitors: A Neuroinformatics perspective. *CNS & Neurological Disorders-Drug Targets* **13(3)** 391-401.
 47. Shaheena Banu, Nasimudeen R. Jabir, Nanjappa C. Manjunath, C. K. Firoz, **M.A. Kamal**, Mohd Shahnawaz Khan, Shams Tabrez (2014) Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients. *CNS & Neurological Disorders-Drug Targets* **13(3)** 402-407.
 48. Mohammad Zubair Alam, Absarul Haque, Qamre Alam, **M.A. Kamal**, Adel M Abuzenadah (2014) A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer's Disease Pathogenicity: An Update *CNS & Neurological Disorders-Drug Targets* **13(3)**, 383-390.
 49. **M.A. Kamal** (2014) Molecular linkage between Alzheimer Diseases and type 2 Diabetes Mellitus – Volume I. *CNS & Neurological Disorders-Drug Targets*. **13(2)**, 192-196 (Editorial).
 50. Sajjad Karim, Zeenat Mirza, **M.A. Kamal**, Adel M Abuzenadah, Esam Ibrahim Azhar, Mohammed Hussein Al-Qahtani, Sayed Sartaj Sohrab (2014) An association of virus infection with Type 2 diabetes and Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets* **13(3)**, 429-439.
 51. **M.A. Kamal**, Nigel H. Greig, Shubha Priyamvada, N.A. Arivarasu, Nasimudeen R. Jabir, Shams Tabrez (2014) Linkage of Alzheimer's and type 2 diabetes mellitus *via* aberrant insulin signaling and inflammation. *CNS & Neurological Disorders-Drug*

- Targets **13(2)**, 338-346.
52. Kothandaraman Narasimhan, Meenakumari Govindasamy, Kalamegam Gauthaman, **M.A. Kamal**, Adel M Abuzenadeh, Mohammed Al-Qahtani, Rajaraman Kanagasabai (2014) Diabetes of the brain: Computational approaches and Interventional strategies. *CNS & Neurological Disorders-Drug Targets*, **13 (3)** 408-417.
 53. Firoz Ahmed, Juned Asghar Ansari, Zahid Eqbal Ansari, Qamre Alam, Gan SH, **M.A. Kamal** and Ejaj Ahmad (2014) A molecular bridge: Connecting Diabetes type II and Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 312-321.
 54. Muhammad I. Nasser, Fehmida Bibi, Mohammed H. Alqahtani, Adeel G. Chaudhary, Esam I. Azhar, **M.A. Kamal** and Muhammad Yasir (2014) Role of gut microbiota in obesity, type 2 diabetes and Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 305-311.
 55. Nasimudeen R. Jabir, **M.A. Kamal**, Adel Mohammad Abuzenadah, Gan SH, Mohammed Nabil Alama, Saleh S. Baesa, Shams Tabrez (2014) Alzheimer's and Type 2 diabetes management via common enzyme targeting. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 299-304.
 56. Tanveer A. Dar, Ishfaq A. Sheikh, Showkat A. Ganie, Riyasat Ali, Laishram R. Singh, Gan SH, **M.A. Kamal** and Mohammad A. Zargar (2014) Molecular linkages between Diabetes and Alzheimer's disease: Current scenario and future prospects *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 290-298.
 57. Y. Dai and **M.A. Kamal** (2014) Fighting Alzheimer's disease and type 2 diabetes: Pathological links and treatment strategies. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 271-282.
 58. Munvar Miya Shaik, Gan Siew Hua, **M.A. Kamal** (2014) Epigenomic approach in understanding Alzheimer's disease and type 2 diabetes mellitus. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 283-289.
 59. Mohd Hassan Baig, Syed Mohd. Danish Rizvi, Shazi Shakil, **M.A. Kamal** and Saif Khan (2014) A Neuroinformatics study describing molecular interaction of cisplatin with acetylcholinesterase: a plausible cause for anticancer drug induced neurotoxicity. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 265-270.
 60. Taoufik Nedjadi, Absarul Haque, Qamre Alam, Adeel G Chaudhary, Adel M Abuzenadah, Ghazi Damanhour, Gan SH, **M.A. Kamal** (2014) Genomic Linkage between Alzheimer's Disease and Type 2 Diabetes. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 203-212.
 61. Zeenat Mirza, Ashraf Ali, Ghulam Md Ashraf, **MA Kamal**, Adel M Abuzenadah, Adeel G. A. Choudhary, Ghazi A Damanhour and Ishfaq Ahmed Sheikh (2014) Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 213-225.
 62. Qurrat ul Ain, Nigel H. Greig, Muhammad S. Nawaz and **M.A. Kamal** (2014) Exploring N¹-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment. *CNS & Neurological Disorders-Drug Targets*, **13(2)**, 197-202.
 63. Khan NM, Ahmad A, **Kamal MA**, Mushtaq G, Ashraf GM (2014) Current challenges to overcome the management of type 2 diabetes mellitus and associated neurological

disorders. *CNS Neurol Disord Drug Targets*, 13(8): 1440-1457.

2013

1. Nassim Djabou, Mohamed El Amine Dib, Hocine Allali, Andreas Benderb, **MA Kamal**, Said Ghalem, Boufeldja Tabti (2013) Evaluation of antioxidant and antimicrobial activities of the phenolic composition of Algerian *Arbutus unedo* L. roots. *Pharmacognosy J.*, 5(6), 275-280.
2. Haque, Q. Alam, M.Z. Alam, **M.A. Kamal** (2013) Global Current Trends in Drug Designing for Management of Type-2 Diabetes and Neurodegenerative Disorders. *Drug Designing (Editorial)* 2:e120. doi: 10.4172/2169-0138.1000e120
3. Almas Iqbal, Iqra Ahmad, Mohammad Hassan Khalid, Nawaz MS, Siew Hua Gan, **M.A. Kamal** (2013) Nanoneurotoxicity to nanoneuroprotection using biological & computational approaches. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* (in press). 31:3, 256-284, DOI: 10.1080/10590501.2013.829706 (<http://dx.doi.org/10.1080/10590501.2013.829706>).
4. Hocine Allali, Ilyas Chikhi, Mohamed El Amine Dib, Alain Muselli, Nadia Fekih, Nawel Meliani, Mohammad A.Kamal, Boufeldja Tabti, Jean Costa (2013) Antioxidant activity and chemical analysis of *Mentha spicata* cultivated from west northern region of Algeria by headspace solid phase micro-extraction and hydro-distillation. *Natural Products An Indian Journal*, 9 (6), 258-263.
5. N. Khebichat, K. Nekkaz, S. Ghalem, Sajid Rashid, **M.A. Kamal** (2013) Conformational search on the tripeptides structure by molecular dynamics: Study of L,L-Gly-Phe-Phe, L,L-Phe-Gly-Phe, and L,L-Phe-Phe-Gly. *Drug Designing*, 2: 106. doi: 10.4172/2169-0138.1000106.
6. Sidra Batool, Saba Ferdous, Hira Iftikhar, **M.A. Kamal**, Sajid Rashid (2013) In silico screening for identification of novel Aurora kinase inhibitors by molecular docking, dynamics simulations and ligand-based hypothesis approaches. *Enzyme Engineering*, 2: 106 doi: 10.4172/eeg.1000106.
7. S. Shakil, Adnan Ahmad, Shams Tabrez, Ghulam M. Ashraf, Aftab A.P. Khan, Adel M. Abuzenadah and **M.A. Kamal** (2013) A 'region-specific treatment strategy' to address the problem of drug resistance by NDM-1-producing pathogens. *Enzyme Engineering*, 2: 107 doi: 10.4172/eeg.1000107.
8. Sidrah Batool, Muhammad Sulaman Nawaz and **M.A. Kamal** (2013) In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid. *Investigational New Drugs*. (<http://link.springer.com/article/10.1007%2Fs10637-013-9944-9>; DOI 10.1007/s10637-013-9944-9).
9. Yu QS, Reale M, **MA Kamal**, Holloway HW, Luo W, Sambamurti K, Ray B, Lahiri DK, Rogers JT, Greig NH (2013) Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α -synuclein synthesis, interleukin-1 β release, and cholinergic action. *Antiinflamm. Antiallergy Agents Med. Chem.* 12(2): 117-28.
10. Gjumrakch Aliev, Shams Tabrez, Nasimudeen R. Jabir, Mark E. Obrenovich, Prakash Reddy, Yi Li, Geoffrey Burnstock, Ramón Cacabelos and **M.A. Kamal** (2013) Link between Cancer and Alzheimer Disease via Oxidative Stress Induced by Nitric Oxide-Dependent Mitochondrial DNA Overproliferation and Deletion. *Oxidative Medicine and Cellular Longevity* (doi: 10.1155/2013/962984).

<http://www.ncbi.nlm.nih.gov/pubmed/23691268> in press).

11. Ain QU, Seemab U, Rashid S, Muhammad Sulaman Nawaz, **M.A. Kamal** (2013) Prediction of structural of human WNT-CRD (FZD) complex for computational drug repurposing. PLOS ONE. 2013;8(1):e54630. doi: 10.1371/journal.pone.0054630.
12. Y Tan, W Lao, L Xiao, Z Wang, W Xiao, MA Kamal, J. Paul Seale, Xianqin Qu (2013) Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome with Chinese herbal extracts in high-fat-diet fed rats. Evidence-Based Complementary and Alternative Medicine (<http://www.hindawi.com/journals/ecam/aip/306738/>).
13. Tabrez S, Priyadarshini M, Urooj M, Shakil S, Ashraf GM, Khan MS, **Kamal MA**, Alam Q, Jabir NR, Abuzenadah AM, Chaudhary AGA, Damanhour GA. (2013) Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 31(1): 67-98. <http://www.tandfonline.com/doi/full/10.1080/10590501.2013.763577>.
14. Sidrah Batool, Muhammad Sulaman Nawaz, Nigel H. Greig, Mohammad Rehan and **M.A. Kamal** (2013) Molecular Interaction study of N¹-p-fluorobenzyl-cymserine with TNF- α , p38 kinase and JNK kinase. Antiinflamm. Antiallergy Agents Med. Chem. 12(2):129-35.
15. CC Clement, J Gonzalez, **M.A. Kamal**, M Philipp (2013) Molecular docking, in silico structure-based design, and kinetic evaluation of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 245.
16. Mahmood Rasool, Sara Zahid, Arif Malik, Abdul Manan, Irshad Begum, Mahmood Husain Qazi, Adeel Chaudhary, Mohammed Hussain Alqahtani, **M.A. Kamal** and Ishfaq Ahmed Sheikh (2013) An update on Cervical cancer. J. Cancer Sci. Ther., Vol. 5 (10), 227.

2012

1. F. Lebbad, M. Merad, N. Boussalah and S. Ghalem, Jabir NR, **M.A. Kamal** (2012) Study of interaction between complexes of copper (II) and melanin pigment by molecular modeling. Enzyme Engineering (1:e107. doi: 10.4172/eeg.1000e107 <http://www.omicsgroup.org/journals/EEG/EEG-1-e107.php?aid=10521> in press).
2. Riyasat Ali, Ishfaq Ahmed Sheikh, Nasimudeen R. Jabir and **M.A. Kamal** (2012) Comparative view of couple of decade's research on Cholinesterase inhibition. Am. J. Neuroprotection & Neuroregeneration, 4, 136-144.
3. Jummanah Jarullah, Soad AlJaouni, Sharma MC, Bushra M.S.J, **M.A. Kamal** (2012) Screening for Glucose-6-Phosphate Dehydrogenase Deficiency In Jeddah Female Neonates. Enzyme Engineering (1: 105. doi: 10.4172/eeg.1000105; <http://www.omicsgroup.org/journals/EEG/EEG-1-105.php?aid=10533>).
4. Yury Kaminsky, Armenuhi Poghosyan, Lyudmila Tikhonova¹, Hector H. Palacios, **Kamal M.A.**, Elena Kosenko, Gjumrakch Aliev (2012) Glycolytic and proteolytic metabolism in erythrocytes from elderly and demented patients. Am. J. Neuroprotection & Neuroregeneration 4, 73-77.
5. Diwan. A, Khan Shahida Aziz, Patel Rishi, Krishna Kavita, C K Firoz, **MA. Kamal** (2012) Spectrum from obesity to neurodegenerative disorder. Am. J. Neuroprotection

- & Neuroregeneration 4, 31-39.
6. Sheikh IA., Ali R, Dar TA, Kamal M.A. (2012) An overview on potential neuroprotective compounds for management of Alzheimer's Disease. *CNS & Neurological Disorders-Drug Targets*, 11(8):1006-11.
 7. Riyasat Ali, Zeenat Mirza, Ghulam Md Ashraf, **Kamal M.A.**, Ghazi A. Damanhour, Adel M. Abuzenadah, Adeel GA Chaudhary, Ishfaq Ahmad Sheikh (2012) New anti cancer agents: Recent development in tumor therapy. *Anticancer Res.* 32 (7), 2999-3005.
 8. Nasimudeen R. Jabir, Shams Tabrez, Shazi Shakil, Ghulam Md Ashraf, Ghazi A. Damanhour and Kamal M.A (2012) Nanotechnological Approach Towards Anticancer Research. *Int. J. NanoMed.* (7), 4391-4408.
 9. Kamal M.A. (2012) Status of Tyrosine Hydroxylase in the Healthy and Parkinson's Brain. *CNS & Neurological Disorders-Drug Targets*. 11(4), 336-339 (Editorial).
 10. Tabrez S., Jabir NR., Shakil S., Greig NH., Alam Q., Abuzenadah AM., Damanhour GA., **Kamal M.A.** (2012) A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson's Disease. *CNS & Neurological Disorders-Drug Targets*, 11(4):395-409.
 11. Priyadarshini M., **Kamal M.A.**, Nigel H. Greig, Reale M., Abuzenadah A., Adeel G.A. Chaudhary, Damanhour G.A., (2012) Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. *CNS & Neurological Disorders-Drug Targets*, 11(4):482-489.
 12. Wajihullah Khan, Priyadarshini M., Haytham A. Zakai, **Kamal M.A.**, Q. Alam, A (2012) Brief overview of tyrosine hydroxylase and α -synuclein in the Parkinsonian brain. *CNS & Neurological Disorders-Drug Targets*, 11(4):456-462.
 13. Zahida Parveen, Muhammad S. Nawaz, Shazi Shakil, Nigel H. Greig, **Kamal M.A.** (2012) Molecular Docking Study of Catecholamines and PPCA with Tyrosine Hydroxylase. *CNS & Neurological Disorders-Drug Targets*, 11(4):463-468.
 14. Reale M., Pesce M., Priyadarshini M., **Kamal M.A.** and Patruno A. (2012) Mitochondria as an easy target to oxidative stress events in PD. *CNS & Neurological Disorders-Drug Targets*, 11(4):430-438.
 15. Shakil S, **M.A. Kamal**, Tabrez S., Abuzenadah A., Adeel G.A. Chaudhary, Damanhour G.A (2012) Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. *CNS & Neurological Disorders-Drug Targets*, 11(2):142-147.

2011

1. Patruno A, Shams Tabrez, Amerio P, Pesce M, Vianale G, Di Luzio S, Tulli A, Franceschelli S, Grilli A, Muraro R, **M.A. Kamal**, Reale M (2011) Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450, Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines. *CNS & Neurological Disorders-Drug Targets*, 10 (8): 936-944 (IF 3.62).
2. Shaheena Banu, Nasimudeen R. Jabir, C N Manjunath, Shakil S, **M.A. Kamal** (2011) Role of c-peptide in the progress of metabolic syndrome in type-2 Diabetes Mellitus. *CNS & Neurological Disorders-Drug Targets* 10(8): 921-927.
3. M. Reale, **M.A. Kamal**, L. Velluto, D. Gambi, M. Di Nicola, N.H. Greig (2011) Relationship between inflammatory mediators, A β levels and APOE genotype in Alzheimer disease. *Curr. Alzh. Res.*, 9(4): 447-457. (IF 4.953).
4. A.A. Al-Jafari, Shakil S, M. Reale and **M.A. Kamal** (2011) Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: a combined experimental and

- computational approach. *CNS & Neurological Disorders-Drug Targets*, 10(8): 928-935. (IF 3.62).
5. Y. Tan, L-Q. Sun, **M.A. Kamal**, J.P. Seale, X. Qu (2011) Suppression of RBP4 by RNA oligonucleotide in 3T3-L1 cells and mice. *BBA (Mol & Cell Biol. Lipids)*, 1811(12): 1045-53 (IF 5.084).
 6. Shakil S, R. Khan, S. Tabrez, Q. Alam, J. Naseemuddin, M.I. Suleman, N.H. Greig, **M.A. Kamal** (2011) Interaction of acetylcholinesterase with cyclophosphamide: a molecular modelling and docking study. *CNS & Neurological Disorders-Drug Targets*, 10 (7): 845-848 (IF 3.62).
 7. M. Reale, **M.A. Kamal**, Veronica Bellante and N.H. Greig (2011) Butyrylcholinesterase inhibitors modulate cytokines production in peripheral blood mononuclear cells. *Alzheimer's & Dementia: The J. Alzh. Assoc.*, 7 (4), Supp., 671-672 (IF 5.902).
 8. Shakil S, E.I. Azhar, S. Tabrez, **M.A. Kamal**, N.R. Jabir, G.A. Damanhour, Q. Alam (2011) New Delhi metallo-beta-lactamase (NDM-1): An update. *J. Chemotherapy*, 23(5): 263-265.
 9. Y. Tan, **M.A. Kamal**, Z-Z Wang, W. Xiao, J.P. Seale, X Qu (2011) Chinese herbal extracts (SK0506) as a potential candidate for the therapy of metabolic syndrome. *Clin. Sci.* 120 (7): 297-305 (IF in 2009: 3.982).
 10. **M.A. Kamal**, P. Klein (2011) Determination of sugars in Honey by Liquid Chromatography. *Saudi J. Biol. Sci.* 18(1): 17-21.

2010

11. M.A. Kamal, M. Reale & A.A. Al-Jafari (2010) Multiple approaches to analyze the data for rat brain acetylcholinesterase inhibition by cyclophosphamide. *Neurochem. Res.* 35(10):1501-1509.
12. **M.A. Kamal**, P. Klein (2010) Estimation of BTEX in Groundwater by Using Gas Chromatography-Mass Spectrometry. *Saudi J. Biol. Sci.* 17(3): 205-208.

2009

13. M. Reale, N.H. Greig & M.A., Kamal (2009) Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's disease. *Mini Rev. Med. Chem.* (IF 3.132), 9(10): 1229-1241.
14. **M.A. Kamal**, Y. Tan, J.P. Seale & X Qu (2009) Targeting BuChE-Inflammatory Pathway by SK0506 to Manage Type 2 Diabetes and Alzheimer Disease. *Neurochem. Res.* 34(12), 2163-2169.
15. **M.A. Kamal**, N.H. Greig and M. Reale (2009) Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administered in Alzheimer's disease. *Anti-Inflamm. Anti-Allergy Agents in Med Chem.* 8(1): (Mini-review), 85-100 (<http://www.bentham.org/cmcaiaa/CurrentIssue.htm#9>).

2008

16. **M.A. Kamal**, X. Qu, Q-s Yu, D. Tweedie, H.W. Holloway, Y. Li, Y. Tan, N.H. Greig (2008) Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor

and experimental Alzheimer drug candidate, enzyme kinetic analysis. *J. Neural Trans.* 115(6): 889-898.

17. **M.A. Kamal**, P. Klein, W. Luo, Y. Li, H.W. Holloway, D. Tweedie, N.H. Greig (2008) Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. *Neurochem. Res.* 33(5): 745-753.
18. Greig NH, Utsuki T, Yu QS, **Kamal MA**, Holloway HW, Perry T, Tweedie D, Li Y, Giordano T, Alley GM, Chen DM, Rogers JT, Sambamurti K, and Lahiri DK (2008) Dissociation between the potent β -amyloid protein pathway inhibition and cholinergic actions of the Alzheimer drug candidates phenserine and cymserine. In: *Advances in Alzheimer's and Parkinson's Disease: Insights, Progress, and Perspectives*, (Eds. A. Fisher, M. Memo, F. Stocchi, and I.Hanin), Springer Science + Business Media, USA, 445-462.

2007

19. **M.A. Kamal** & P Klein (2007) Estimation of Fatty Acids in Oils by Gas Capillary Chromatography. *SAUDI J BIOL SCI.* 14 (1), 17-20.

2006

20. **M.A. Kamal**, Q-S. Yu, H.W. Holloway, D. Tweedie, P. Klein, N.H. Greig (2006) Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. *J. Alz. Disease*, 10(1), 43-51.
21. D. Tweedie, A. Brossi, DeM. Chen, Y-W. Ge, J. Bailey, Q-S. Yu, **M.A. Kamal**, K. Sambamurti, D.K. Lahiri, N.H. Greig (2006) Neurine, an acetylcholine autolysis product, elevates secreted amyloid β -precursor protein and amyloid β peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease? *J. Alz. Disease*, 10(1), 9-16.
22. **M.A. Kamal**, A.A. Al-Jafari, Qian-sheng, Yu & N.H. Greig (2006) Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. *Biochem. Biophys. Acta* 1760, 200-206.

2005

23. **M.A. Kamal** (2005) Interaction of antifolates with enzymes of the de novo purine pathway in human CCRF-CEM leukaemia cells: Monitored using HPLC linked with UV and radioactive detectors. *Em. Med. J.* 23(2), 155-164.
24. **M.A. Kamal**, A.A. Al-Jafari & N.H. Greig (2005) Interaction of new anti-Alzheimer's disease agents with cholinesterase. *J. Neurochem.* 94(s2), 168.

2004

25. **M.A. Kamal** & R.I. Christopherson (2004) Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates. *Int. J. Biochem. Cell Biol.*, 36, 545-551.

2002

26. **M.A. Kamal**, N.H. Greig & A.A. Al-Jafari (2002) A new, simple and economical approach to analyse the inhibition kinetics of acetylcholinesterase using tolserine. *Em. Med. J.*, 20(3), 333-337.

2001

27. **M.A. Kamal** & A.A. Al-Jafari (2001) A graphical kinetic analysis model for the inhibition of acetylcholinesterase by anti-Alzheimer's drug, tacrine. *S. J. Biol. Sci.*; 8(2), 113-122.

2000

28. **M.A. Kamal**, N.H. Greig, A.S. Alhomida & A.A. Al-Jafari (2000) Kinetics of human acetylcholinesterase inhibition by novel experimental Alzheimer therapeutic agent, tolserine. *Biochem. Pharmacol.*, 60 (4), 561-570.
29. S. Alhomida, A.S. Al-Rajhi, M.A. Kamal & A.A. Al-Jafari (2000) Kinetic analysis of the effect of Cognex (tacrine) on human retinal acetylcholinesterase activity. *Toxicology*, 147, 33-39.
30. **M.A. Kamal**, A.S. Alhomida, A.A. Al-Rajhi & A.A. Al-Jafari(2000) Thermodynamic analysis of human retinal acetylcholinesterase inhibition using an anti-Alzheimer's drug, tacrine, through the development of a dual substrate and temperature model. *Proc. Natl. Sci. Coun., Life Sci. (B)*, 24 (3), 108-115.
31. **M.A. Kamal**, F.H. Nasim & A.A. Al-Jafari (2000) Graphical kinetic approach for estimation of various new constants for inhibition of acetylcholinesterase by cisplatin. *Pak. J. Biol. Sci.*, 3 (6), 920-923.
32. **M.A. Kamal** & A.A. Al-Jafari (2000) Dual substrate model for novel approach toward kinetic study of acetylcholinesterase inhibition by diazinon. *J. Enz. Inhib.*, 15/2, 201-213.
33. **M.A. Kamal** & A.A. Al-Jafari (2000) Mode of inhibition of bovine retinal acetylcholinesterase by gallamine triethiodide in vitro. *Pak. J. Biol. Sci.*, 3 (5), 767-771.
34. A.A. Al-Jafari, **M.A. Kamal**, A.S. Alhomida and N.H. Greig (2000) Kinetics of rat brain acetylcholinesterase inhibition by two experimental Alzheimer's disease drugs, phenserine and tolserine. *J. Biochem. Mol. Biol. Biophys.*, 4, 323-335.

1999

35. **M.A. Kamal** (1999) Effect of some anti-cancer drugs on human erythrocyte acetylcholinesterase (topic of Ph.D. thesis), Department of Chemistry, Islamia University, Bahawalpur, Pakistan.
36. **M.A. Kamal**, F.H. Nasim & A.A. Al-Jafari (1999) Human erythrocyte acetylcholinesterase inhibition by cis-diamminediaquaplatinum (II): a novel kinetic approach. *Cancer Lett.*, 138, 115-119.
37. **M.A. Kamal** & A.A. Al-Jafari (1999) Kinetic constants for the inhibition of camel retinal acetylcholinesterase by the carbamate insecticide lannate. *J. Biochem. Mol. Toxicol.*, 13 (1), 41-46.
38. **M.A. Kamal** & A.A. Al-Jafari (1999) Comparative kinetics of the inhibition of human plasma butyrylcholinesterase by tacrine, estimated by new and classical methods. *J. Neurochem.*, 73, S50-S50.

1998

39. A.A. Al-Jafari, **M.A. Kamal**, N.H. Greig, A.S. Alhomida & E. Perry (1998) Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine. *Biochem. Biophys. Res. Comm.*, 248 (1), 180-185.
40. A.A. Al-Jafari, **M.A. Kamal** & A.S. Alhomida (1998) On the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro. *Cell. Biol. Toxicol.*, 14(3), 167-174.
41. A.A. Al-Jafari, F. Al-Khwyter & **M.A. Kamal** (1998) Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin. *Cancer. Lett.*, 128, 79-86.
42. A.A. Al-Jafari, **M.A. Kamal** & A.S. Alhomida (1998) Sensitivity of bovine retinal acetylcholinesterase (EC 3.1.1.7) toward tacrine: Kinetic characterization. *J. Biochem. Mol. Toxicol.*, 12(4), 245-251.

1997

43. **M.A. Kamal** (1997) Dual temperature model for the estimation of energetic parameters for acetylcholinesterase inhibition by cyclophosphamide. *Biochem. Mol. Biol. Int.*, 43 (3), 571-581.
44. A.A. Al-Jafari, **M.A. Kamal**, and A.S. Alhomida (1997) Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. *J. Enzyme Inhibition*, 11, 275-283.
45. **M.A. Kamal** (1997) Effect of sevin on kinetic parameters of camel retina acetylcholinesterase. *Biochem. Mol. Biol. Int.*, 42 (2), 235-246.
46. A.S. Alhomida, **M.A. Kamal** & A.A. Al-Jafari (1997) Evaluation of the nature of camel retinal acetylcholinesterase inhibition by hexamethonium. *J. Enz. Inhib.*, 12, 303-311.
47. **M.A. Kamal** (1997) Effect of malathion on kinetic parameters of acetylcholinesterase (EC 3.1.1.7) in vitro. *Biochem. Mol. Biol. Int.*, 43 (1), 89-97.
48. **M.A. Kamal** (1997) Investigation of the effect of lannate on kinetic parameters of retinal acetylcholinesterase: Slightly concave mixed type of inhibition system. *Biochem. Mol. Biol. Int.*, 43 (5), 1183-1193.
49. **M.A. Kamal**, M.S. Bakkar & A.A. Al-Jafari (1997) Estimation and correlation of IC₅₀ for the inhibition of human erythrocyte acetylcholinesterase by cis-Diamminediaquaplatinum (II). *Anticancer Res.*, 17(6), 4483-4486.
50. **M.A. Kamal** (1997) Kinetics of human erythrocyte acetylcholinesterase inhibition by cis-Diamminediaquaplatinum (II). *Anticancer Res.*, 17,4487-4492.

1996

51. A.A. Al-Jafari & **M.A. Kamal** (1996) Optimization and kinetic studies of human erythrocyte membrane-bound acetylcholinesterase. *Biochem. Mol. Biol. Int.*, 38, 577-586.
52. **M.A. Kamal** & A.A. Al-Jafari (1996) The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. *Prep. Biochem. & Biotech.*, 26, 105-119.

53. **M.A. Kamal** & A.A. Al-Jafari (1996) Estimation and correlation of IC₅₀ with time for the inhibition of human erythrocyte acetylcholinesterase by cisplatin. *Cell. Pharmacol.*, 3, 45-48.
54. A.S. Duhaiman, A.S. Alhomida, N. Rabbani, **M.A. Kamal** & A.A. Al-Jafari (1996) Purification and characterization of acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom. *Biochimie*, 77, 46-50.
55. **M.A. Kamal**, F.H. Nasim & A.A. Al-Jafari (1996) Investigation of the effect of anti-neoplastic drugs: cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. *Biochem. Mol. Biol. Int.*, 39, 293-302.
56. **M.A. Kamal**, F.H. Nasim, & A.A. Al-Jafari (1996) In vitro inhibition of human erythrocyte acetylcholinesterase (EC 3.1.1.7) by an antineoplastic drug methotrexate. *Mol. Cell. Biochem.*, 159, 47-53.
57. A.A. Al-Jafari & **M.A. Kamal** (1996) Investigation of the effect of tetrahydroaminoacridine on turnover kinetics of camel (*Camelus dromedarius*) retina acetylcholinesterase. *Biochem. Mol. Biol. Int.*, 39, 917-922.
58. Al-Jafari, F. Al-Khwyter, **M.A. Kamal** & A.S. Alhomida (1996) Kinetics for camel (*Camelus dromedarius*) retina acetylcholinesterase inhibition by methotrexate in vitro. *Jpn. J. Pharmacol.*, 72, 49-55.
59. F. Al-Khwyter, **M.A. Kamal** & A.A. Al-Jafari (1996) The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity. *Toxicol. Lett.*, 87, 69-76.
60. A.A. Al-Jafari, **M.A. Kamal**, A.S. Duhaiman & A.S. Alhomida (1996) Kinetics of the inhibition of acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom by local anesthetics: procaine & tetracaine. *J. Enz. Inhib.*, 11, 123-134.
61. **M.A. Kamal** (1996) Characterization of human erythrocyte membrane-bound acetylcholinesterase inhibition by cisplatin at reversible phase. *Anticancer Res.*, 16 (6B), 3725-3730.

1995

62. A.A. Al-Jafari, **M.A. Kamal**, A.S. Duhaiman & A.S. Alhomida (1995) Acetylcholinesterase from desert cobra (*Walterinnesia aegyptia*) venom: Optimization and Kinetics study. *Mol. Cell. Biochem.*, 151, 21-26.
63. A.A. Al-Jafari, A.S. Duhaiman & **M.A. Kamal** (1995) Inhibition of human acetylcholinesterase by cyclophosphamide. *Toxicology*, 96, 1-6.
64. A.A. Al-Jafari, **M.A. Kamal** & A.S. Duhaiman (1995) The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. *J. Enz. Inhib.*, 8, 281-289.

1994

65. Matin, **M.A. Kamal** & F.H. Nasim (1994) Energetic studies of acetylcholinesterase inhibition by 2-(diethylamino)-N-(2, 6-dimethylphenyl) acetamide. *Pak. J. Pharm.*, 6, 73-83.
66. A.A. Al-Jafari & **M.A. Kamal** (1994) The preparation and Kinetic properties of multiple forms of chicken brain acetylcholinesterase. *Cell. Biochem. Funct.*, 12, 209-216.

Ex-Editor in Chief:

1. Enliven: Journal of Genetics, Molecular and Cellular Biology (<http://enlivenarchive.org/editorialboard-genetics.php>)
2. Enliven: Neurology and Neurotechnology (<http://enlivenarchive.org/editorialboard-neurology-neurotechnology.php>)
3. Enliven: Pharmacovigilance and Drug Safety! (<http://enlivenarchive.org/editorialboard-pharmacovigilance-drug-safety.php>)

Middle East Regional Editor For the following journals:

1. Current Drug Metabolism (<http://benthamscience.com/journals/current-drug-metabolism/editorial-board/#top>)
2. CNS & Neurological Disorders - Drug Targets (<http://benthamscience.com/journals/cns-and-neurological-disorders-drug-targets/editorial-board/#top>)
3. Medicinal Chemistry (<http://benthamscience.com/journals/medicinal-chemistry/editorial-board/#top>)

Executive Guest Editor:

1. Current Pharmaceutical Design
2. Current Drug Metabolism
3. Medicinal Chemistry

Associate Editor:

1. BMC Neuroscience (<http://www.biomedcentral.com/bmcneurosci/about/edboard>)
2. Frontiers in Aging Neuroscience (<https://loop.frontiersin.org/people/196702/overview>)

Section Editor:

Coronaviruses

MEMBERSHIP IN EDITORIAL BOARD OF SCIENTIFIC JOURNALS:

1. Journal of Medicinal Chemistry
2. CNS & Neurological Disorders-Drug Targets
3. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy journal (http://www.dovepress.com/articles.php?pa=editorial_board&journal_id=32&l=p9c510BYmtN4q6IRD0eS4h2j150125)
4. Enzyme Engineering (Executive Editor; <http://www.omicsgroup.org/journals/editorialboardEEG.php>)
5. Am. Journal of Neuroprotection and Neuroregeneration
6. Drug Designing (<http://www.omicsgroup.org/journals/editorialboardDDO.php>)
7. Research Journal of Endocrinology and Metabolism (<http://www.hoajonline.com/endocrinolmetab/editorialboard>)
8. Journal of Medical Disorders (<http://www.hoajonline.com/meddisord/editorialboard>)
9. Journal of Neurological Disorders (<http://www.esciencecentral.org/journals/editorialboardJND.php>)
10. Pharmacognosy Magazine (<http://www.phcog.com/editorialboard.asp>)

11. Journal of Molecularbiology and Techniques
(<http://www.elynsgroup.com/EBMList.aspx>)
12. The Open Biochemistry Journal (<http://benthamscience.com/open/journal/render-ebm.php?journalID=tobiocj>)
13. Journal of Advance Health Sciences
14. Journal of Disease Markers (<http://austinpublishinggroup.org/disease-markers/editorialBoard.php>)
15. Epigenetic Diagnosis & Therapy
16. Jacobs Journal of Drug Metabolism and Toxicology
(<http://www.jacobspublishers.com/index.php/journal-of-drug-metabolism-and-toxicology-editorial-board>)
17. Protein & Peptide Letters
18. International Archives of Endocrinology Clinical Research (IAECR;
http://clinmedjournals.org/International-Archives-of-Endocrinology-Clinical-Research/Endocrinology-Clinical-Research_editorial_board.php)
19. Journal of Neurology and Psychology (<http://www.avensonline.org/medical/journal-of-neurology-and-psychology/editorial-board-30/>)
20. Journal of Chemical and Pharmaceutical Research (<http://jocpr.com/editorial-board.html>)

Guest Editor for a special issue:

1. The journal ‘CNS & Neurological Disorders-Drug Targets’ (CNSND-DT) dedicated to “Status of tyrosine hydroxylase in the healthy and Parkinson's brain” for 2011 (<http://www.benthamscience.com/cdtnsnd/Special-Issues.htm>).
2. CNSND-DT dedicated to “Molecular linkage between Alzheimer Diseases and type 2 Diabetes” for 2012 (http://www.benthamscience.com/cdtnsnd/HT/Kamal2_revised.pdf).
3. Current Drug Metabolism dedicated on “Global Trends in Nanotechnological Approaches in Various Health Issues” (<http://benthamscience.com/journal-files/special-issue-details/cdm/CDM-SII20140127-01.pdf>).
4. CNSND-DT dedicated to “LINKAGE OF NEURODEGENERATIVE DISORDERS WITH OTHER HEALTH ISSUES” for 2013 (<http://benthamscience.com/journal-files/special-issue-details/cnsnddt/CNSNDDT-SII20140122-02.pdf>).
5. Current Alzheimer Research dedicated to “Alzheimer's disease: From molecular mechanisms to psychobiological perspectives” (CAR; <http://benthamscience.com/journal-files/special-issue-details/CAR-SII20150317-01.pdf>)
6. CNSND-DT dedicated to “Linkage of CNS and immunology with psychology: searching for new pharmacological targets” for 2015 (<http://benthamscience.com/journal/special-issues.php?journalID=cnsnddt>).
7. Enzyme Engineering
(http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=EN&cid=222548)
8. ‘Evidence-Based Complementary and Alternative Medicine’ dedicated to “Enzyme-Inhibitors from Medicinal Plants in Management of Various Disorders” (<http://www.hindawi.com/journals/ecam/si/416917/cfp/>).

9. 'Evidence-Based Complementary and Alternative Medicine' dedicated to "Medicinal Plants in Management of Type 2 Diabetes and Neurodegenerative disorders" (<http://www.hindawi.com/journals/ecam/si/543132/cfp/>).
10. 'Medicinal Chemistry' dedicated to "Medicinal Chemistry: Neurological and Endocrinological Disorders" (<http://benthamscience.com/journal-files/special-issue-details/MC-SII20140613-01.pdf>).
11. Current Psychopharmacology dedicated to "Psychopharmacology of Attention Deficit Hyperactivity Disorder (ADHD)" (<http://www.benthamscience.com/cpsp/ht/hamidrezamehboobi.pdf>).
12. Journal of Molecular and Genetic Medicine dedicated to "Computational study of neuro-enzymes interaction with potential therapeutic candidates for management of neurological disorders" (<http://www.omicsonline.com/open-access/specialissue-molecular-genetic-medicine.php>).
13. Journal of Neurological Disorders dedicated on "Challenges in therapeutic intervention for the suppression of neurological disorders" (<http://www.esciencecentral.org/journals/editorialboardJND.php>).
14. 'Saudi J. Biol. Sci.' dedicated on "Biological aspect of various global health issues" (<http://www.journals.elsevier.com/saudi-journal-of-biological-sciences/call-for-papers/special-issue-on-biological-aspect-of-various-global-health/>).
15. Recent Patents on Nanomedicine dedicated on "Current Status of Recent Patents on Nanomedicines"
16. Current Aging Science dedicated on "Current updates on understanding the purpose and mechanism of Aging" (<http://www.benthamscience.com/journal/index.php?journalID=cas>).
17. 'Evidence-Based Complementary and Alternative Medicine' dedicated to "Herbal Medicines and Natural Products Targeting G Protein-Coupled Receptors in Management of Diseases" (<http://www.hindawi.com/journals/ecam/si/749261/cfp/>).
18. Current Pharmaceutical Design dedicated on "Managing strategies for diverse diseases: Challenges from bench to bedside in successful drug discovery and development" (<http://benthamscience.com/journal-files/special-issue-details/CPD-SII20150521-01.pdf>).
19. CNSND-DT dedicated to "Association of CNS disorders with other health issues" for 2015 (<http://benthamscience.com/journal/index.php?journalID=cnsnddt>).
20. Journal of Diabetes Research (JDR; dedicated on "Natural Products and Diabetes" (<http://www.hindawi.com/journals/JDR/si/715632/cfp/>).
21. Current Drug Metabolism (CDM), dedicated on "Frontier research view on drug discoveries for different diseases" (<http://benthamscience.com/journals/current-drug-metabolism/special-issues/#top>).

22. Current Medicinal Chemistry dedicated on “UPDATES ON NEURODEGENERATIVE AND METABOLIC DISORDERS: SYNTHETIC, BIOLOGICAL AND COMPUTATIONAL ASPECTS
23. Current Topics in Medicinal Chemistry (CTMC) dedicated on "updates on therapeutic research for management of neurodegenerative disorders"
<http://benthamscience.com/journals/current-topics-in-medicinal-chemistry/special-issues/#top>
24. Oxidative Medicine and Cellular Longevity (OMCL), dedicated on “Phytochemicals Targeting Oxidative Stress and Inflammation in Chronic Degenerative Diseases”
<http://www.hindawi.com/journals/omcl/si/618790/cfp/>
25. Current Pharmaceutical Design (CPD), dedicated on “Frontier research view on current pharmaceutical designing for management of different diseases”
26. Neural Plasticity, dedicated on “Nonmotor Disturbances in Parkinson’s Disease: Mechanisms and Clinical Implications”
(<http://www.hindawi.com/journals/np/si/804069/cfp/>)
27. Research Topic of Frontiers in Aging Neuroscience: "Neuroscientific Research for Management of Dementia"
(<http://journal.frontiersin.org/researchtopic/4966/neuroscientific-research-for-management-of-dementia>)
28. Special Issue on "Nonpharmacologic Interventions in Prevention and Treatment of Hypertension" in International Journal of Hypertension
<file:///C:/Users/profm/Downloads/490393.pdf>
29. Research Topic on The Alzheimer's Disease Challenge for Frontiers in Neuroscience, section Neurodegeneration
<http://journal.frontiersin.org/researchtopic/5903/the-alzheimers-disease-challenge>
30. Current Drug Metabolism (CDM), dedicated on “Nanomedicines in cancer therapy: Advances and challenges” Guest Editor(s): Sohail Akhter, Ziyaur Rahman, Mohammad A. Kamal, Ponnurengam M. Sivakumar)
<http://benthamscience.com/journals/current-drug-metabolism/special-issues/#top>
31. Seminars in Cancer Biology dedicated on “Current Vision on Target Enzymes for Cancer Therapy”
32. ‘Overviews on Current Stem Cells Research for Neurological Therapy’ in Current Stem Cell Research & Therapy Code for submission: BSP-CSCRT-2017-HT39
33. "From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy and Neuro-Psychological Factors" in Oxidative Medicine and Cellular Longevity
<file:///C:/Users/profm/Downloads/403525.pdf>
34. Metabolic & Immune Disorders - Drug Targets dedicated on “Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management”

<http://benthamscience.com/journal-files/special-issue-details/EMIDDT-SII20160725-01.pdf>

35. Journal: Seminars in Cancer Biology dedicated on “Cancer Nanotherapeutics: Targeted medicine, therapeutic vaccination and Challenges with cancer nanomedicines”

36. Current Pharmaceutical Design dedicated on “Current Challenges in management of neurological disorders”

37. Seminars in Cancer Biology dedicated on “Autoimmune diseases and Cancer Comorbidity: Current understanding of immune mediated-Pathogenesis and treatment”

38. Current Pharmaceutical Design dedicated on “Complementary and integrative medicine or personalized health care for cancer and chronic inflammatory diseases” (Guest Editors: Ilaria Peluso, Mohamed Abdel-Daim, Nagendra Sastry Yarla and Mohammad Amjad Kamal <https://benthamscience.com/journals/current-pharmaceutical-design/author-guidelines/#top>)

39. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS dedicated on “Migraine comorbidities and/or migraine-mimics in vascular, metabolic, endocrine and immune-mediated disorders”
file:///C:/Users/profm/Downloads/Call%20for%20papers_CNS%20&%20Neurological%20%20Disorders-Drug%20Targets.pdf

40. Endocrine, Metabolic & Immune Disorders - Drug Targets dedicated on “Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus”
<https://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/special-issues/#top>

41. Analytical Cellular Pathology: Oxidative damage in cancers: biomarkers, impacts and therapy dedicated on “Nonpharmacologic Interventions in Prevention and Treatment of Hypertension” <https://www.hindawi.com/journals/ijhy/si/490393/cfp/>

42. Current Pharmaceutical Design (CPD), dedicated on “Current Challenges in the management of neurological disorders” BMS-CPD-2019-HT-52

43. Medicinal Chemistry dedicated on "Current views on Medicinal Chemistry versus Green Chemistry for management of broad spectrum health issues" - Hot code (BMS-MC-2019-HT-2) <https://benthamscience.com/journals/medicinal-chemistry/special-issues/>

44. Current Drug Metabolism (CDM), dedicated on “Challenges in the discovery of novel therapeutic agents in cancer” - BMS-CDM-2019-HT-8

45. Research Topic proposal on 'Bioactive Compounds and Diabetes Mellitus: Prospects and Challenges' with *Frontiers in Nutrition*
<https://www.frontiersin.org/research-topics/11702/bioactive-compounds-and-diabetes-mellitus-prospects-and-challenges>

46. "Alzheimer Disease and Sleep Disorders; Insights into the Possible Disease Connections and the Potential Therapeutic Targets" for publication in "CNS & Neurological Disorders - Drug Targets" <https://bentham.manuscriptpoint.com/.../Submission/sub.../1663/m>

47. Special Issue "How to Optimize the Use of Antibiotics in Human and Animal Health Care? – A Time to Act".

https://www.mdpi.com/journal/antibiotics/special_issues/use_human_animal

48. "Synopsis on Antimicrobials Challenges—From Dentistry to Environmental Visions"

https://www.mdpi.com/journal/antibiotics/special_issues/anti_challenges

49. GUT Microbiota and Cardiovascular Pharmacology; Journal: Pharmacological Research (IF 5.6) <https://www.journals.elsevier.com/pharmacological-research>

50. Viral disease and natural products, with a particular focus on COVID-19; Current Pharmaceutical Design <https://bentham.manuscriptpoint.com/journals/CPD>

51. Stem Cell Transplantation Therapy in Neurological Disorders: Current Status and Future Directions for the journal of "Current Neuropharmacology"

<https://benthamscience.com/journal-files/special-issue-details/CN-SII20200601-01.pdf>

52. Targeting cellular signalling pathways in cancer by natural compounds for the Journal of Current Medicinal Chemistry (BMS-CMC-2020-HT-36).

<https://benthamscience.com/journal-files/special-issue-details/CMC-SII20200619-02.pdf>

53. Linkage of COVID-19 and Neurodegenerative disorders for "CNS & Neurological Disorders - Drug Targets" BMS-CNSNDDT-2020-HT-13

<https://bentham.manuscriptpoint.com/submit/Submission/submissionForm/2018/m>

54. Journal: Coronaviruses; Current research updates on Coronavirus Outbreak: Overviews of its global impact and consequences

<https://benthamscience.com/journal-files/special-issue-details/COVID-SII20200714-01.pdf>

55. Journal: Medicinal Chemistry; "Insights on SARS-COVID-19 and its linkage with cancer using rational drug design: Bioactive compounds using computational approaches"

<https://benthamscience.com/journal-files/special-issue-details/MC-SII20200622-01.pdf>

Editor of eBooks:

1. Challenges in Cure of Parkinson's Disease and Future Perspectives (<http://esciencecentral.org/ebooks/challenges-in-cure-of-parkinsons-disease-and-future/>)
2. Enzymoics (<http://esciencecentral.org/ebooks/enzymoics/>)

TECHNICAL AND SCIENTIFIC ROLES:

- ✓ International Scientific Advisory Board of "The International Institute of Anticancer Research" (IIAR - Advisory Board, Scientific Committee... <http://www.iiar-anticancer.org/iiar/committee.htm>)
- ✓ Forum for European-Australian Science and Technology Cooperation

- ✓ Member of National Scientific Advisory Board of Saudi Society for Genomic and Molecular Oncology

PROFESSIONAL SOCIETIES:**1999:**

1. European Society for Toxicology *In Vitro*
2. International Society for Neurochemistry
3. Society for Experimental Biology and Medicine
4. Canadian Society of Pharmaceutical Sciences

2002:

Australian Society for Biochemistry and Molecular Biology

2004-09:

International Society for Neurochemistry (ISN)

2006:

International Stroke Society

2006-2008:

Australian Institute of Medical Scientists (Intermediate Member)

From 2005:

The Royal Australian Chemical Institute Inc. (Member Chartered Chemist while promoted to Fellow status in 2011;

http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=En&cid=112210)

From 2010:

The American Society for Biochemistry and Molecular Biology (ASBMB)

Society for Enzymology

From 2012:

Saudi Medicine Society

Scientific Member of Chair "Yousef Abdul Latif Jameel therapeutic applications in the Prophet's medicine"

From 2013:

Saudi Society for Genomics and Molecular Oncology

Consul of "InterNations Sydney Academic Networking (INSAN) group" since Nov 2013

ORCID: <http://orcid.org/0000-0003-0088-0565>


Weblinks:

<http://www.benthamscience.com/journal/index.php?journalID=cas>
<http://www.pubfacts.com/author/Mohammad+A+Kamal>
<http://www.hindawi.com/journals/ecam/si/749261/cfp/>
<http://gcbu.webs.com/>
<http://www.engii.org/workshop/ICE2014December/ShowOrganizerDetails.aspx?personID=3847>
<https://benthamscience.com/journals/current-pharmaceutical-design/editorial-board/#top>
<http://benthamscience.com/journal/editorial-board.php?journalID=cnsnddt#top>
<http://benthamscience.com/journal-files/special-issue-details/cdm/CDM-SII20140127-01.pdf>
<http://benthamscience.com/journal-files/special-issue-details/cnsnddt/CNSNDDT-SII20140122-02.pdf>
<http://www.journals.elsevier.com/saudi-journal-of-biological-sciences/call-for-papers/special-issue-on-biological-aspect-of-various-global-health/>
<http://www.phcog.com/editorialboard.asp>
<http://makamalcreativewriting.yolasite.com>
<http://internationalfriends.com.au/2014/03/31/from-pakistan-to-australia/>
<http://www.benthamscience.com/cdm/HT/M.A.Kamal.pdf>
<http://www.hindawi.com/journals/ecam/si/416917/cfp/>
<http://www.benthamscience.com/cdtcnsnd/HT/Kamal3.pdf>
<http://www.hindawi.com/journals/ecam/si/543132/cfp/>
<http://www.benthamscience.com/cpsp/HT/HamidrezaMehboobi.pdf>
<http://www.hmaward.org.ae/site/winner-2003-uae.php>
<http://www.omicsgroup.org/journals/editorialboardDDO.php>
<http://www.hoajonline.com/endocrinolmetab/editorialboard>
<http://www.hoajonline.com/meddisord/editorialboard>
http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=EN&cid=213088
http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=EN&cid=106035
http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=En&cid=213559
http://www.benthamscience.com/cdtcnsnd/HT/Kamal2_revised.pdf
http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=EN&cid=112210
http://kfmrc.kau.edu.sa/Content.aspx?Site_ID=141&lng=En&cid=117968
<http://scholar.google.com/citations?user=bDjqLrMAAAAJ&hl=en>
http://www.researchgate.net/profile/Mohammad_KAMAL
<https://www.scopus.com/authid/detail.uri?authorId=56340070000>
<http://benthamscience.com/journal-files/special-issue-details/MC-SII20140613-01.pdf>
<http://omicsgroup.org/journals/flyers/enzyme-engineering.pdf>
http://clinmedlibrary.com/International-Archives-of-Endocrinology-Clinical-Research/Endocrinology-Clinical-Research_editorial_board.php

Links related to conferences:

<http://www.engii.org/workshop/ICE2014December/ShowOrganizerDetails.aspx?personID=3847>

<http://stressmanagement.global-summit.com/scientific-program.php?day=3&sid=732&date=2015-07-15>



Further Qualifications:

- Bachelor Degree in Science - Gomal University – 1984
- Dec 2005 **STATEMENT OF COMPETENCIES** (Adv Dipl of Lab Ope 6853), TAFE
- March 2006 **E-business** (3701A), TAFE
- July 2006 **Outreach Access** course (Creative writing), (3492), TAFE
- Jan 2007 **Outreach Access** course (3492), TAFE (Communicate in the workplace...)
- June 2007 **Certificate of Achievement** (Basic First Aid) by Rod at Rooty Hill
- Dec 2007 **Adult Learning and Teaching**, Ultimo TAFE
- July 2008 **Skillmax** studied at AMES Surry Hill
- 24th April 2009 **Personal finance management** course at Werrington TAFE, NSW
- 24th June 2009 **Leadership for Sustainable Living** at Mt Druitt TAFE, NSW
- 24th June 2009 **Survival First Response** through Survival First Response
- 23rd September 2009 **Creative Writing** Course at Mount Druitt College (TAFE)
- 10th Dec 2009 **Health Services assistance**, The Hills College –TAFE (13 units out of 15)
- Feb 2010 to Dec 2011 **Diploma of Remedial MT: Applied Health Life Sciences** (18277) HLT50307 (passed 16 units)
- Feb 2011 **Basic Body and Therapy 1** of Professional training in Dr Vodder's MLD
- 20th Nov 2015 **Child protection awareness training** under "Primary Ethics" program
- 12th Nov 2016 – 10th Dec 2016 **Managing Staff Performance**, The St George TAFE
- 15th Feb 2017 **School Governance and Legal Compliance** - AISNSW
- 17th Feb 2017 **Optimising the Impact of Classroom Observations** by AISNSW
- January 2017 **Leading Change and Innovation for Senior Managers** (TAFE)
- 25th Feb 2017 **Child Protection Legislation** online via AISNSW
- May 2019 **Statement of attainment in Chaplaincy** (Eva Burrows College)
- Nov 2016 **Diploma of Leadership & Management** (TAFE) – 7 units completed
- 8 Feb 2018 **BGA Capital Grants Application Briefing**, AISNSW
- 2019 Various courses (online) and onsite 3 days induction training under SLHD
- Governance Online Module 1 - **Introduction to School Governance**, AISNSW
- May 2019 Governance Online Module 2 - **School Governance**, AISNSW
- 17th June 2019 Governance Online Module 3 - **Legal Compliance**, AISNSW

- 18th June 2019 Governance Online Module 4 - **Financial Compliance**, AISNSW
- 29 Aug 2017 NESA (**CRICOS** Approvals) Briefing
- 29 Aug 2017 NESA (**ESOS** National Code) Briefing
- 13-Jun-19 **Aboriginal Culture - Respecting the Difference**, NSW Health
- 29-Apr-19 **Child Wellbeing and Child Protection - Part 1**, NSW Health
- 16-Jun-19 **Child Wellbeing and Child Protection - Part 2**, NSW Health
- 16-Jun-19 **Child Wellbeing and Child Protection 1 - Non Patient Facing Health Workers**, NSW Health
- 02-May-19 **Fire and Evacuation**, NSW Health
- 30-Apr-19 **Hazardous Manual Tasks**, NSW Health
- 07-May-19 **Infection Prevention and Control Principles for non-clinical staff**, NSW Health
- 17-Mar-19 **Introduction to Health Emergency Management and Emergency Procedures**, NSW Health
- 08-May-19 **Introduction to Work, Health and Safety**, NSW Health
- 09-May-19 **Privacy Module 1 - Know Your Boundaries**, NSW Health
- 15-May-19 **Promoting Acceptable Behaviour in the Workplace**, NSW Health
- 16-May-19 **Security Awareness - All Staff**, NSW Health
- 20-May-19 **Violence Prevention and Management - Awareness**, NSW Health
- 22-Apr-19 **Waste Management**, NSW Health

Training:

- 22 & 29 November 2015 - Primary Ethics Teacher Training (2 Full days)
- 20th Nov 2015 - Child protection awareness online training under “Primary Ethics”
- 6th and 7th Nov 2017 - Youth Mental Health First Aid Training by MHFA Australia
- 25th Nov 2017 – Psychology First Aid Training by Australian Red Cross
- March 19th, 2018 - Accidental Counselling and Communicating with Others at Baulkham Hills, NSW
- 04th Feb 2019 - AAC ALL OF THE TIME: Giant Steps Tasmania
- 05th Feb 2019 – Positive Behaviour Support: Part 1; Giant Steps Tasmania
- 26,27th April & 4th May 2019 - Cultural Support Induction Training by NSW Health SLHD
- 13th June 2019 - In-language development of resources training by NSW Health SLHD
- 9th July 2019 - HIV diagnosis, appropriate care and treatment by NSW Health

RESUME

Prof. Mohammad Amjad Kamal (PhD; FRACI C Chem)

- 18th July 2019 - Working with Groups by NSW Health SLHD
- 15th Feb 2020 - Somatic Therapy training by A. Patterson/Wisdom Body
- 24th March 2020 – NDIS Worker Orientation Module (Quality, Safety and You)

Working with Children Check clearance: WWC0898178E valid until 21 Nov 2021

Skills: Editing, Research, Teaching, Leading, Chaplaincy, Anti-stress therapy etc..



Mohammad Amjad Kamal

[FOLLOW](#)

Post-Doctorate

Primary
King Fahd Center for Medical Research, King Abdulaziz University
Jeddah, Saudi Arabia

Director
Novel Global Community Educational Foundation (NGCEF), Hebersham
Hebersham, Australia

Overview

Bio

1,273
Network

672
Publications

29
Editorial Contributions

Impact

33,081
Total Views

4,042
Profile Views

672
Total Publications

17,987
Publication Views

3,335
Publications Downloads

[View Full Impact](#)

29 Editorial Contributions

RT 3 Edited Research Topics

26 Edited Publications

[View Editorial Contributions](#)

Brief Bio

Dr. Mohammad Amjad Kamal is a Distinguish Adjunct Professor at King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia, where he was full Professor from March 2011 to March 2013. Prof. Kamal's overall biochemical research output had culminated in more than 450 publications in internationally respected journals, and 61 abstracts in ...

[View Full Bio and Expertise](#)

Editorial Roles

Guest Associate Editor for
Neurodegeneration

Frontiers in Neuroscience
[Open for submissions](#)